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Abstract 
 
Novel Biocompatible/Antimicrobial Materials 
Based on Nitric Oxide Release/Generation 
 
By 
 
Wenyi Cai 
 
Chair: Mark E. Meyerhoff: 
 
 
Thrombus formation and bacterial infection are two major problems that are associated 
with indwelling biomedical devices. In this dissertation work, coatings that are capable of 
releasing or generating nitric oxide (NO), a potent anti-platelet and antimicrobial agent, 
have been developed to solve the biocompatibility issues. 
First, diazeniumdiolate doped-poly(lactic-co-glycolic acid) (PLGA)-based NO release 
coatings with controllable NO release profiles can be prepared with lifetimes of up to 15 
d at room temperature (23 C) and 10 d at 37 C.  The NO release coatings exhibit 
significant antibiofilm properties after one week incubation in a CDC biofilm reactor, 
which provided both renewable nutrient sources and shear forces.  In particular, 
compared to a silicone rubber surface, an NO release film with a base layer of 30 wt% 
dibutyhexyldiamine diazeniumdiolate (DBHD/N2O2) mixed with poly(lactic acid) (PLL) 
exhibited ~ 98.4% reduction in biofilm biomass of S. aureus and ~ 99.9% reduction for 
E. coli at 37 °C.   
NO can also be generated from endogenous NO donors such as S-nitrosothiols 
(RSNOs) by utilizing catalytic materials.  A carboxyl-ebselen-based layer-by-layer (LbL) 
film was fabricated by alternatively assembling carboxyl-ebselen linked 
xix 
 
polyethylenimine (e-PEI) and alginate (Alg) onto substrates followed by salt annealing 
and cross-linking.  After soaking in sheep blood for 24 h, a polyurethane catheter coated 
with (e-PEI/Alg)50 exhibit an NO flux of 310
-10
 mol cm
-2
 min
-1
 in a reservoir containing 
physiological levels of RSNO and thiols.  The LbL film is also capable of generating 
superoxide (O2
•-
), a potent antimicrobial agent.  In-vitro antimicrobial tests demonstrated 
that a (e-PEI/Alg)50 film is capable of killing 98.2 % E. coli in solution and reducing ~87% 
E. coli surface coverage within 2 h at 37 C.  
In addition, a novel CuO nanoparticle-doped polyurethane film with less leaching of 
copper and minimized toxicity issue compared with a similar film doped with Cu
0
 
nanoparticles is prepared.  The film is capable of catalytically generating NO for 16 days 
at 37 C.  
With their proven potential antithrombotic or antimicrobial properties, the developed 
NO release and NO generation coatings are expected to improve the biocompatibility of 
indwelling surfaces, reduce the medical cost and save patients’ lives. 
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Chapter 1 Introduction 
 
 
Thrombus formation and bacterial infection are two common problems that lead to 
dysfunction of indwelling biomedical devices such as catheters, vascular grafts and 
stents.  As a potent antiplatelet and endogenous antimicrobial agent, nitric oxide (NO) 
has been shown to prevent thrombus formation,
1
 reduce bacterial adhesion on surfaces
2
 
and disperse existing biofilms through signaling.
3, 4
  Therefore, an artificial surface that is 
able to release or generate NO is expected to provide a potential solution for common 
biocompatibility issues that create risk for patients.  While polymer coatings that contain 
NO donors are able to release NO from the polymeric materials, NO generation materials 
are a group of catalytic coatings that are able to convert endogenous NO donors, such as 
S-nitrosothiols (RSNOs), into NO. 
  
In this dissertation work, both strategies are employed to improve the biocompatibility 
of polymeric surfaces.  Firstly, a diazeniumdiolate-doped poly(lactic-co-glycolic acid) 
(PLGA)-based NO release coating with a controllable NO release pattern is shown to 
prevent biofilm formation under various conditions.
5
  In contrast, for new 
organoselenium-based NO generation materials, the antimicrobial activity is attributed to 
the superoxide (O2
•-
) production coming from the reaction between the selenolate and 
oxygen.
6
  In this thesis, the NO generation and superoxide (O2
•-
) production capability of 
an ebselen (non-toxic RSe species)-based Layer-by-Layer (LbL) coating is demonstrated 
and the potential antithrombotic and antimicrobial property is proven by in vitro 
experiments.
7
  In addition, the catalytic activities of various NO generation coatings 
containing different copper species are examined.  It will be shown that polyurethane 
films doped with CuO naoparticles can be used as alternatives to previously developed 
copper(II)-based NO generation coatings to produce simple and effective NO generation 
materials. 
2 
 
1.1 Thrombus Formation and Bacterial Infection Related Complications for 
Indwelling Biomedical Devices 
Although indwelling biomedical devices have played a key role in the healthcare 
system to save patients’ lives, developing a truly “biocompatible” device surface remains 
a challenge.  The thrombogenic nature and susceptibility to bacterial infection of 
polymeric materials that are employed for indwelling biomedical devices often lead to 
device complications, and further cause problems such as significantly increased medical 
costs, long-term hospitalization, amputation or even patient death.  
 
 
 
Figure 1.1. Thrombus formation on a foreign surface.
8
 
 
As shown in Figure 1.1, when a device is implanted into the blood stream, adsorption 
of proteins including fibrinogen, fibronectin and von Willebrand Factor (vWF) will take 
place within seconds.  These proteins will further interact with receptors on the plasma 
membranes of platelets and facilitate platelet adhesion, primarily through the binding of 
the glycoprotein GPIIb/IIIa receptor with fibrinogen, and GPIb with vWF.
9
  Upon 
contacting the foreign surface, platelets become activated, which will further lead to 
conformation changes and the excretion of intracellular granulates containing the 
coagulation factors VII and XI, adhesion molecules P-selectin and vWF that will further 
3 
 
induce activation and aggregation of more platelets, facilitating the coagulation cascade, 
and eventually lead to thrombus formation on the foreign surface within hours.
9
   
 
Figure 1.2. Surface initiated blood coagulation cascade (intrinsic system).
10
 
 
The coagulation cascade contains a series of zymogen activation steps triggered 
through surface contact (intrinsic system) or tissue factor (extrinsic system).  The 
implantation of a medical device (with a negatively charged surface created by the device 
material or protein absorption) will trigger the first step of the intrinsic pathway: the 
activation of the blood zymogen FXII (Hageman factor) into active enzyme FXIIa.  The 
activation of FXII will further lead to the activation of Factor XI and eventually lead to 
the formation of thrombin through a series of zymogen activation steps (shown in Figure 
1.2).  Thrombin, the key enzyme that is capable of turning fibrinogen into fibrin, also 
activates Factor XIII, which will further cross-link and stabilize fibrin into an insoluble 
gel that traps platelets and red blood cells in a thrombus. 
Thrombus formation can lead to significant consequences such as complete obstruction 
of stents,
10
 occlusion of catheters
11
 and small diameter vascular grafts,
12
 errant results of 
implantable chemical sensors,
12
 embolic complication with artificial hearts
13
 and 
extensive blood damage during extracorporeal membrane oxygenation.
13
  These types of 
complications occur at a rate between 2% to 10% depending on the device.
10
   
4 
 
 
 
Figure 1.3. Four-step formation process of a biofilm.
14
  
 
Bacterial infection, especially biofilm-induced infection, is another problem with 
indwelling devices.  As shown in Figure 1.3, biofilm formation is a four-step process: 1) 
the attachment of planktonic bacterial cells onto the surface to form a cell monolayer; 2) 
the accumulation of bacterial cells resulting from increased cell adhesion and 
proliferation; 3) formation and maturation of a biofilm including production of 
extracellular polysaccharides; and 4) detachment of biofilm that will further lead to 
infection of new surfaces.
14
  While the initial attachment occurs within 1~2 h and is 
reversible, after 2~3 h, irreversible adhesion will occur and further lead to biofilm 
formation after ~24 h.
2
  Therefore, the biofilm community is capable of irreversibly 
colonizing the surface while retaining nutrients and protecting the microorganisms inside 
the matrix with the help of the extracellular polysaccharides.  Once a biofilm is formed 
on indwelling device surfaces, it is difficult to kill the bacterial cells by conventional 
antibiotics due to their inability to penetrate well through the biofilm matrix and the 
heterogeneous chemical environment of the biofilm.
15
  It is reported that in some cases, 
~1000 fold dose of conventional antibiotics is necessary to treat bacterial cells in a 
biofilm compared to their planktonic forms.
2
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The annual infection rate in the United States is reported to be 4.3 % for orthopedic 
implants and 7.4 % for cardiovascular implants and the most common pathogens that 
cause bacterial infection include Gram-positive Staphylococcus aureus (S. aureus), 
Staphylococcus epidermidis (S. epidermidis) and Gram-negative Escherichia coli (E. 
coli) and Pseudomonas aeruginosa (P.aeruginosa).
2
  Although the infection rates vary 
widely with patients and devices, in some cases, the consequences can be severe and 
fatal.  
  In order to reduce the rate of device complication, various strategies have been used to 
improve the compatibility of an indwelling surface to prevent problems like thrombus 
formation and bacterial infection.   
Since protein adsorption is an important initial stage for both thrombus and biofilm 
formation, one strategy is to create an antifouling surface that is capable of greatly 
reducing protein adsorption.  For example, poly(ethylene glycol) (PEG) grafted surfaces 
have been widely used and have been proven to reduce thrombus formation
16
 and biofilm 
formation.
17
  This type of coating, however, tends to auto-oxidize at ambient conditions 
and gradually loses its anti-fouling functionality.
18
  Recently, Semprus Biosciences Corp. 
(Cambridge, MA) has successfully developed an antifouling coating with long-term 
stability based on zwitterionic polysulfo- and polycarboxylbetaines.
19
  The surface tightly 
binds water and forms a barrier that will prevent protein adsorption, thus greatly reducing 
thrombus and biofilm formation on the surface. 
Another strategy is to immobilize antithrombotic or antimicrobial agents or sites on the 
surface to form a functional coating.  For example, heparin-based coatings and devices 
have achieved both in vitro and in vivo success and have become commercially available 
to prevent thrombus formation.
20
  However, for coatings that do not release antimicrobial 
agents, including coatings with immobilized polysaccharides, surfactants, 
polyelectrolytes multilayers (PEMs), positively charged polymer brushes, quaternary 
ammonium compounds or proteins,
21-24
 the effectiveness varies with bacterial species
2, 18
 
and might be weakened through formation of conditioning films. 
An alternative strategy is to use coatings that can release antimicrobial agents and co-
immobilize antithrombotic agents.  Although antibiotics such as cephalothin, 
carbenicillin, amoxicillin, cefamandol, gentamicin and vancomycin can be incorporated 
6 
 
into coatings to prevent infection,
25
 the resistance of an increasing number of bacterial 
strains and biofilms to antibiotics has limited the practical application of most antibiotic-
release coatings.
26
  Therefore, novel antimicrobial agents have to be developed.  Silver 
salts (e.g., silver sulfadiazine) have been applied widely into commercial coatings to 
prevent bacterial colonization on catheter surfaces
11
 and a non-thrombogenic and biocidal 
coating has been fabricated by incorporating silver nanoparticles into surfaces with co-
immobilized heparin.
27
  However, the cytotoxicity and genotoxicity of silver-based 
species remain a potential issue. 
22
 
1.2 Antithrombotic and Antimicrobial Surface with Nitric Oxide Release 
1.2.1 Nitric oxide as endogenous antithrombotic and antimicrobial agent 
   
 
Figure 1.4. Biological production of nitric oxide.
28
 
 
Nitric oxide (NO) is well recognized for its remarkable biological roles in the body 
including its antithrombotic, anti- cell proliferation, vasodilating, anti-microbial and anti-
inflammatory effects.
29, 30
  NO is enzymatically synthesized by nitric oxide synthase 
(NOS) through the conversion of L-arginine and oxygen into L-citrulline and NO with 
the help of nicotinamide adenine dinucleotide phosphate (NADPH) (see Figure 1.4).   
Several isoforms of NOS have been identified including endothelial NOS (eNOS), 
neuronal NOS (nNOS) and induced NOS (iNOS),
31
 and both eNOS and nNOS are also 
known as constitutive NOS (cNOS).
32
  As a macrophage-derived form, iNOS is not 
expressed, but is induced by endotoxin and inflammatory mediators such as cytokines.
31
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While the functionality of cNOS is regulated by Ca
2+
 fluxes and further binding to 
calmodulin, iNOS functions independently of calcium and is able to release large 
amounts of NO continuously.
29
  A healthy endothelial cell surface, with an NO flux of 
0.5~410
 -10
 mol cm
-2
 min
-1
, is known as the most non-thrombotic surface.
33
  The amount 
of NO released per unit time from fully induced macrophages could be a thousand times 
higher than that released by NOS from endothelial cells,
29
 which contributes to the 
important role of NO in the immune system and its antimicrobial and antiviral activity. 
NO is reported to be an antiplatelet agent that is capable of preventing platelet 
adhesion,
34
 aggregation
35
 and recruitment
36
 into a growing thrombus.  The antiplatelet 
activity of NO contributes to the antithrombotic property of the endothelial cell surface.  
NO inhibits platelets through a cyclic guanosine monophosphate (cGMP) mediated 
signaling process by firstly binding to the heme moiety of soluble guanylyl cyclase 
(sGC), more specifically, NO-sensitive guanylyl cyclase (NO-GC),
37
 and further causing 
an increase in cGMP and concurrent decrease in intracellular Ca
2+
.  Meanwhile, cGMP is 
able to increase cyclic adenosine monophosphate (cAMP) levels indirectly through 
phosphodiesterase III (PDE III), which will also cause a decreased Ca
2+
 flux.  Since 
cGMP inhibits thrombin-mediated activation of phosphoinositide 3-kinase (PI-3 kinase) 
and both PI-3 kinase activation and Ca
2+
 are important in promoting the formation of an 
active conformation of glycoprotein IIb/IIIa on the outer platelet membrane, this will 
further decrease platelet association with fibrinogen and cause platelet disaggregation.
30
  
As stated above, NO is also a potent antimicrobial agent.  As a reactive free radical, 
NO is capable of interacting with reactive oxygen species such as hydrogen peroxide 
(H2O2) and superoxide (O2
•-
) to form different antimicrobial agents, including 
peroxynitrite (ONOO
-
), nitrogen dioxide (NO2), dinitrogen trioxide (N2O3) and 
dinitrogen tetroxide (N2O4). These species can further cause oxidative stress and lead to 
DNA, protein or cell lipid membrane damage of most microbes.
38, 39
  NO is also capable 
of nitrosating the cysteine or tyrosine residues of proteins to cause protein dysfunction.
2
  
In addition, NO can cause ion depletion and inhibit metabolic enzymes.
37
  While a high 
level of NO produced by the immune system is able to kill microbes, low levels of NO 
have been reported to prevent biofilm formation and disperse established biofilms 
through a signaling process
4, 40-42
 mediated by cyclic di-GMP (c-di-GMP).  As a second 
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messenger, c-di-GMP regulates the transition from microbial biofilm to planktonic 
bacterial cells in response to cell-cell signals or environmental cues.  Increased c-di-GMP 
levels facilitates the biofilm mode, and the decrease of c-di-GMP leads to biofilm 
dispersal.
4
  Diguanylate cyclases (DGCs) and specific phosphodiesterases (PEDs) are 
responsible for the biosynthesis and degradation of c-di-GMP, respectively.  Similar to 
the well-known NO/cGMP pathway that utilizes NO sensing domains in the eukaryotic 
system, it is reported that NO will also increase PEDs activity (e.g., binding to the heme 
of the PER-ARNT-SIM (PAS) domain present in some PDEs in P. aeruginosa
4
) and lead 
to a decrease in c-di-GMP levels, which will further lead to biofilm dispersal.
41, 43
  
1.2.2 NO release coatings based on diazeniumdiolates (NONOates)  
The antiplatelet, antimicrobial and antibiofilm properties of NO make it a potential 
candidate to solve the biocompatibility issues related with indwelling devices.  However, 
since NO rapidly reacts with oxygen and is scavenged by oxyhemoglobin to form 
methaemoglobin and nitrate under in vivo conditions,
44
 it is challenging to handle NO as 
a gas or a dissolved form in aqueous solution.  Therefore, NO donors such as organic 
nitrates and nitrites, metal-NO complexes, diazeniumdiolates (NONOates) and S-
nitrosothiols (RSNOs) have been utilized as more stable alternative forms of NO.
45-47
  By 
incorporating synthetic NO donors into polymeric coatings, the coatings are capable of 
releasing NO at the surfaces and are thus termed NO release coatings.  Artificial coatings 
with an NO flux that is equivalent or higher than that is produced by the healthy 
endothelium surfaces (0.5~4 10
-10
 mol cm
-2
 min
-1
), are expected to exhibit similar 
antithrombotic properties due to the antiplatelet effect of NO.  The specific flux required 
for the antimicrobial property of an NO release surface has not yet been reported because 
it likely varies with different bacterial species. 
N-diazeniumdiolates (NONOates) are one of the most widely used NO donors.  As 
shown in Figure 1.5A, an N-diazeniumdiolate consists of a diolate group [N(O
-
)N=O] 
bound to a nitrogen atom of a nucleophile, which can be a primary, secondary or 
polyamine.
48
  One mole of N-diazeniumdiolate decomposes to release two moles of NO 
through a proton-driven mechanism (Figure 1.5A) and the half-life of the 
diazeniumdiolate species can range from seconds, hours, days or even weeks, depending 
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on the structure of the nucleophile.
46
  Diazeniumdiolates such as proli/NONOate and 
spermine/NONOate (see structures in Figure 1.5B) with half-lives of 2 s and 5-50 min, 
respectively, in 0.1 M phosphate at pH 7.4 at 37 C,
49
 have been infused before the 
implantation of a device or incorporated into coatings to prevent thrombus formation.
48
   
 
 
Figure 1.5. A) NO release mechanism from diazeniumdiolates; B) typical structures of 
small molecule diazeniumdiolates; C) structures of DBHD/N2O2 and PLGA. 
 
To improve the stability of the NO release coating, diazeniumdiolates can be 
covalently attached onto the polymer backbone.
50-54
  A facile way to prepare coatings is 
to dope lipophilic diazeniumdiolates into a polymer film and then further coat this layer 
with a top coat of polymer that decreases the leaching of the diazeniumdiolate or product 
amine, but allows rapid diffusion of NO out of the bilayer film.
53, 55, 56
 Previously, our 
group has demonstrated that dibutyhexyldiamine diazeniumdiolate (DBHD/N2O2) 
(Figure 1.5C) can be used as a stable lipophilic NO donor in polymeric membranes to 
release NO with minimal leaching.
57
  Due to the proton-driven NO release mechanism of 
diazeniumdiolates, the challenge of utilizing a DBHD/N2O2 doped coating lies in 
10 
 
controlling the NO release profile and extending its lifetime by controlling the pH within 
the polymeric material.  Recently, poly(lactic-co-glycolic acid) (PLGA) (Figure 1.5C), a 
biodegradable and biocompatible polymer that is approved by the U.S. Food and Drug 
Administration (FDA), was employed as a matrix to promote the NO release from 
DBHD/N2O2 incorporated coatings (with outer layer of polyurethane) and NO release 
intravascular glucose sensors based on such coatings exhibited greatly reduced thrombus 
formation when implanted into the veins of rabbits.
56
 
1.2.3 NO release coatings based on S-nitrosothiols (RSNOs) 
 
Figure 1.6. Structures of endogenous S-nitrosothiols and synthetic SNAP. 
 
Although diazeniumdiolates are widely used as NO donors, they haven’t been 
approved clinically.
46
  S-nitrosothiols (RSNOs), which are also present endogenously, 
have gained popularity as NO donors in fabricating NO release coatings due to their low 
toxicity.  Figure 1.6 shows the structures of a group of endogenous RSNOs including S-
nitrosocysteine (CysNO), S-nitrosoglutathione (GSNO) and S-nitrosoalbumin (AlbSNO).  
RSNOs can also be synthesized by nitrosation of thiols using nitrous acid as a carrier of 
NO
+
 as shown in eq. 1.1a,
58
 and the structure of S-nitroso-N-acetylpenicillamine (SNAP), 
a synthetic RSNO, is also shown in Figure 1.6.  RSNOs can be converted into NO 
through heat, light or catalytic reactions, as shown in eq. 1.1b, and tertiary RSNOs are 
11 
 
more stable than primary ones.
59
  However, Alb-SNO, which binds NO via a cysteine 
residue, is more stable than low molecular weight RSNOs. 
               
RSNOs can be doped
60
 within or covalently
61-63
 attached to polymers to fabricate NO 
release coatings.  Despite the reduced toxicity, since most of the RSNO-release coatings 
rely on heat or light-induced RSNO decomposition, the in clinical application is limited 
due to the ineffectiveness of heat-induced RSNO decomposition under physiological 
conditions and the lack of access to light for indwelling biomedical devices.  In addition, 
the instability of RSNOs in the presence of heat, light, pH change and trace metal ions 
also renders difficulties in the storage of these coatings.
58
   
1.2.4 Antithrombotic and antimicrobial properties of NO release coatings  
The antithrombotic and antimicrobial properties of NO release coatings have been 
demonstrated by both in vitro and in vivo tests.  An NO release coating based on 
DBHD/N2O2, potassium tetrakis(4-chlorophenylborate) (KTpClPB) and poly(vinyl 
chloride) (PVC) has been coated onto a vascular graft and shown to significantly reduce 
thrombus formation compared to a control graft after implantation into a sheep model for 
21 d.
57
  When the toxic KTpClPB additive, which is important in extending the NO 
release lifetime, was replaced by PLGA, a biocompatible polymer, the antithrombotic 
property of the coating was also observed in a rabbit model.
56
  It has also been 
demonstrated that NO release xerogel coatings are capable of reducing bacterial adhesion 
by both static
2
 and parallel plate flow cell studies.
62
  In addition, the NO release xerogel 
coating is capable of preventing biofilm formation by S. aureus in a subcutaneous animal 
model after 8 d of implantation.
64
 
1.3 Antithrombotic and Antimicrobial Surfaces with Nitric Oxide Generation 
Due to limited reservoir of NO donors that can be incorporated into the polymeric 
coatings, NO release materials normally have limited lifetime.  An alternative strategy is 
12 
 
to use catalytic coatings that are capable of generating NO by converting endogenous NO 
donors, such as RSNOs, into NO and these types of coatings are thus called NO 
generation coatings. 
1.3.1 NO generation from copper species 
A series of copper-based materials including copper ion and Cu(II)-complexes are 
capable of converting RSNO into NO.  In 1996, Williams and coworkers demonstrated 
the Cu
+
, which is capable of forming a five- or six-membered ring-structured 
intermediate with RSNOs, is the key species in the RSNO decomposition mechanism by 
Cu
2+
 as shown in eq. 1.2.
58, 65
 
 
Based on this mechanism, Cu(II)-complexes including Cu(II)-DTTCT (DTTCT= 
dibenzo[e,k]-2,3,8,9-tetrapheny-1,4,7,10-tetraazacyclododeca-1,3,7,9-tetraene), Cu(II)-
cyclen and Cu
0
 particles have been utilized in the fabrication of NO generation coatings.  
When reduced by a reducing agent, the reduced Cu(I) form of the Cu(II) complexes (see 
structures of Cu(II)-DTTCT and Cu(II)-cyclen in Figure 1.7) still have open coordination 
sites to interact with RSNO,
66-68
  which contributes to their catalytic activity.  The 
catalytic activity of Cu
0
 particles
69
 comes from the production of Cu
2+
 through surface 
corrosion in solution.  
 
13 
 
 
Figure 1.7. Structures of copper complexes including Cu(II)-DTTCT and Cu(II)-cyclen. 
(DTTCT= dibenzo[e,k]-2,3,8,9-tetrapheny-1,4,7,10-tetraazacyclododeca-1,3,7,9-tetraene). 
 
1.3.2 NO generation and superoxide production from organoselenium species  
 
 
Figure 1.8. Structures of different organoselenium species. 
 
Ever since the discovery that glutathione peroxidase (GPx), a selenoenzyme that 
protects cell from oxidation stress by reducing hydroperoxides using glutathione (GSH), 
can convert RSNO into NO,
70
 organodiselenides including selenocystamine (SeCA, 
Figure 1.8A) and 3, 3’-dipropionicdiselenide (SeDPA, Figure 1.8B) that act as GPx 
mimics have been employed in developing NO generation materials.
71-73
  The RSNO 
decomposition mechanism is shown in eqs. 1.3 a-d.  In the presence of reducing agents at 
neutral pH, the diselenides can be converted into selenolates, which are the key 
intermediates that can reduce RSNOs into NO and thiolates.
71
           
 
14 
 
Interestingly, the reaction of selenolate with oxygen is also known to produce 
superoxide (O2
•-
), which is able to inhibit bacterial adhesion to an organoselenium 
mediated surface.
74
  Superoxide (O2
•-
) is not very reactive itself, but the production of 
hydroxyl radical (HO) through ion-mediated Haber-Weiss reaction (as shown in eq. 1.4 
a-b) will further cause cell damage.
75
  
 
Despite the RSNO decomposition catalytic activity and antimicrobial property of 
aliphatic selenium species, a recent study has shown that the reaction between aliphatic 
selenolates and oxygen is so fast that a significant amount of superoxide (O2
•-
) and 
selenenyl radical (RSe•) are produced, and the accumulation of toxic peroxides and 
radical species through further reactions leads to the known toxicity of aliphatic selenium 
species.
76
  Aliphatic selenium species are also known to trigger a thiol mediated one 
electron reduction of certain enzymes, such as cytochrome C, which also contributes to 
their toxicity.
77
  Consequently, the in vivo toxicity of alkyldiselenides greatly limits their 
potential biomedical applications.  Recently, a series of aromatic selenium species, with 
good GPx activity and reduced in vivo toxicity, have been developed.  For example, the 
drug ebselen (2-phenyl-1,2-benzisoselenazol-3-(2H)-one, Figure 1.8C), is undergoing 
phase III clinic trials in Japan due to its low toxicity, anti-inflammatory and anti-
oxidation properties.
77
  The antimicrobial activity of ebselen and its derivatives have also 
been reported.
78-80
  The catalytic activity of these species for RSNO decomposition, 
however, has not yet been examined.   
1.3.3 Layer-by-Layer (LbL) assembly technique 
Invented in 1966 by Iler and further developed in the 1990s by Dencher and co-
workers, Layer-by-Layer (LbL) assembly has become a powerful and versatile technique 
for surface modification.
81, 82
  As shown in Scheme 1.1A, this process starts with dipping 
a substrate in a polycation solution followed by several washing steps.  This dipping and 
washing process is then repeated for the polyanion and a bilayer of the polycation and 
polyanion is then assembled onto the substrate based on electrostatic interaction as shown 
in Scheme 1.1B.  This process can be further repeated to fabricate LbL films with desired 
15 
 
number of bilayers.  The self-assembly nature and simplicity in the dip-coating 
procedures of this method enables the utilization of automatic LbL assembly systems and 
precise control of film properties.  Based on electrostatic, hydrophobic and a variety of 
other interactions, this method is applicable for different building blocks and substrates.  
Given that various materials can be applied as the substrates, LbL assembly can be a 
universal and convenient method to apply coatings on biomedical devices.  By utilizing 
chitosan,
84
 heparin,
85, 86
 silver species,
87
 enzymes
88
 or antibodies
89
 as building blocks, 
LbL coatings with antifouling, anticoagulation and antimicrobial properties can be 
fabricated for biomedical applications.  Via attachment of aliphatic diselenide species on 
to a polycation and utilizing alginate as the polyanion, the first NO generation coating 
based on the Layer-by-Layer technique has recently been developed.
72
  The stability of 
the conventional LbL films, however, is highly related to factors such as temperature, 
ionic strength and pH, which is more important for weak polyelectrolyte-based LbL 
films.
90, 91
  More homogeneous and stable LbL films can be obtained through annealing 
using salt, heat, pH changes
92, 93
 or cross-linking the films.
90, 91
 
 
 
Scheme 1.1. Schematic illustration of A) experimental procedure of Layer-by-Layer 
assembly: 1 or 3 represents the soaking process in the polycation or polyanion solution, 
and 2 and 4 represent the washing process; B) formation of Layer-by-Layer film on a 
substrate based on electrostatic interaction.
83
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1.3.4 Antithrombotic and antimicrobial properties of NO generation coatings 
The antithrombotic and antimicrobial properties of NO generation coatings have also 
been proven by both in vitro and in vivo tests.  Firstly, all of the NO generation coatings 
based on organoselenium
72
 or copper (II) complexes
66-68
 are able to generate 
physiological levels of NO even after contacting with blood for prolonged periods, 
indicating potential for antithrombotic properties in clinical applications.  The in vivo 
antithrombotic property of a Cu
0
 particle-based NO generation coatings was 
demonstrated by using a porcine artery model with oxygen sensing catheters coated with 
the NO generation coatings.
69
  In addition, synthetic RSNOs such as SNAP can be 
infused into blood to enhance the in vivo antithrombotic performance of NO generation 
coatings and this has been demonstrated using an in vivo extracorporeal circulation 
model.
94
  Utilizing in vitro colony biofilm assays, the antibiofilm properties of a 
polymeric coating based on an organoselenium species loaded within polymethacrylate 
matrix against S. aureus and P. aeruginosa was also reported.
95
  Similar technology was 
developed by Selenium, Ltd. (Austin, TX)
96, 97
 and has been commercialized. 
1.4 Statement of Dissertation Research 
The primary goal of this dissertation work is to develop antithrombotic and 
antimicrobial coatings based on NO release and NO generation materials.  While, 
previous research in this group has focused on the antithrombotic properties of NO 
release coatings, this dissertation work investigates and demonstrates the antibiofilm 
properties of NO release coatings based on diazeniumdiolates (NONOate) in PLGAs.   In 
addition, two types of NO generation coatings based on novel catalysts including ebselen 
and CuO nanoparticles are also developed and these coatings are aimed at reducing the 
toxicity issues and improving the life-time of NO generation coatings.   
In Chapter 2, NO release coatings with tunable NO release profiles are reported based 
on a previously described DBHD/N2O2 in PLGA system.
56
  The NO release mechanism 
is studied by incorporating pH sensitive probes into the films, utilizing the observed 
colors to compare the pH changes and further correlating the color changes with the NO 
release patterns.  The antibiofilm properties of the coatings against different bacterial 
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species are studied using a CDC biofilm reactor at different temperatures.  This work has 
been published in Biomaterials in 2012
5
 and presented at a national conference.
98
   
To reduce the toxicity issue of Se-based NO generation coatings, in Chapter 3, a 
carboxyl derivative of the drug ebselen was synthesized and the RSNO decomposition 
catalytic activity of different organoselenium species were compared.  A Layer-by-Layer 
film containing the ebselen species was fabricated and is shown to be capable of 
generating NO and producing superoxide (O2
•-
).  The potential antithrombotic, 
antimicrobial and antibiofilm properties of the film are also studied.  This work has been 
published in Biomaterials in 2011
7
 and presented at two national conferences.
99, 100
  
In Chapter 4, the differences between the RSNO decomposition catalytic activity of 
Cu(II)-cyclen and Cu(II)-cyclen polyurethane conjugates are compared and the 
mechanism is examined.  A CuO nanoparticle-based polyurethane film is also proposed 
as an alternative to previously developed NO generation materials based on copper-based 
catalyst.  The long-term catalytic activity of the new CuO nanoparticles-based coating is 
also examined.  
Conclusions and future directions are present in Chapter 5.  The potential synthesis 
route of attaching the ebselen derivative onto polyurethane and utilizing of a novel 
copper ligand to substitute cyclen is discussed and the combination of NO generation 
materials with RSNO releasing coating is also proposed in this chapter. 
In the appendix of this dissertation, a fully biodegradable NO release film is fabricated 
by incorporating a spermine-based diazeniumdiolate into a basic matrix composed of 
poly (lactic acid) (PLL) and Ca(OH)2.  This film is capable of releasing NO for 20 h and 
is expected to be further applied onto metal implants to solve infection problems. 
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Chapter 2 Diazeniumdiolate-Doped Poly(lactic-co-glycolic acid)-Based 
Nitric Oxide Release Films as Antibiofilm Coatings 
 
2.1 Introduction 
As discussed in Chapter 1, nitric oxide (NO) is an endogenous biocide that is produced 
in large quantities by macrophages and exhibits antimicrobial properties against a broad 
spectrum of bacteria.  NO is able to kill bacterial cells through oxidative stress caused 
mainly by peroxynitrite (
-
OONO), the product of the reaction of NO with superoxide 
(O2
•-
).  It is also able to nitrosate cysteine and tyrosine residues which will lead to 
dysfunction of bacterial proteins.
1
  While a high level of NO is able to kill bacterial cells, 
a significantly lower level of NO is reported to prevent biofilm formation and disperse 
established biofilm through a signaling process,
2-5
 which is described in detail in Chapter 
1.   
Although the antimicrobial and antibiofilm properties of NO release coatings have 
been studied previously, most in vitro studies have been performed under “static” 
conditions,
6
 which are not normally correlated with the natural life cycle of bacteria.
7
  
Recently, the Schoenfisch group has used a parallel plate flow cell that creates shear 
forces to mimic the natural environment encountered by microbes, and studied the 
decrease in microbial attachment on NO release coatings after 2 h in PBS buffer.
6, 8
  
Compared to this and other previously reported systems, a flow-through CDC (Centers 
for Disease Control and Prevention) biofilm reactor, capable of creating both renewable 
nutrient sources and shear forces, is regarded as a standard tool to study biofilm 
formation under natural conditions for longer time periods with repeatable results.
7
  
As described in Chapter 1, as one of the most widely used NO donors, 
diazeniumdiolates have been utilized to prepare NO release polymer coatings that prevent 
thrombus formation
9
 and reduce bacterial adhesion.
1
  A previously reported poly(lactic-
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co-glycolic acid) (PLGA) and dibutyhexyldiamine diazeniumdiolate (DBHD/N2O2)-
based NO release coating greatly reduced the toxicity issues and has been shown to 
reduce thrombus formation on intravascular glucose sensors in an in vivo rabbit model.
10
  
No previous study, however, has been conducted to correlate the change in pH within the 
PLGA-based bilayer film with the NO release profile, resulting in an unclear mechanism 
for PLGA as an NO release promoter.  Further, such coatings have never been examined 
with respect to antimicrobial/antibiofilm behavior. 
 
 
 
Figure 2.1. A) The appearance of dibutyhexyldiamine diazeniumdiolate (DBHD/N2O2) 
and poly(lactic-co-glycolic) acid (PLGA)-based NO release coating with a bi-layer 
structure on a glass slide; B) Schematic illustration of dibutyhexyldiamine 
diazeniumdiolate (DBHD/N2O2) and poly(lactic-co-glycolic) acid (PLGA)-based NO 
release coating and its cross-section. 
 
Herein, a two-layered NO release coating with a base layer of DBHD/N2O2 doped in 
PLGA and a protective silicone rubber (SR) top coating (see Figure 2.1A for film 
configuration) is examined.  The pH changes in the PLGA layer are visualized by 
incorporating a pH sensitive dye into the coating.  By employing PLGAs with different 
hydrolysis rates as the inner matrix (possessing different ratios of lactic and glycolic acid 
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in the PLGA polymer), the NO release profile of this type of coating can be readily 
manipulated, which in turn, greatly impacts the NO release kinetics.  The antibiofilm 
properties of these new NO release coatings against gram-positive S. aureus and gram-
negative E. coli at room temperature (23 °C) and at physiological temperature (37°C) are 
evaluated after a one-week incubation in a CDC biofilm flow-reactor.   
2.2 Experimental 
2.2.1 Materials 
Acid terminated poly(D, L-lactide-co-glycolide acid) (PLGA) 50:50 (a-50-50) (catalog 
number 719897) was purchased from Sigma-Aldrich (St. Louis, MO) and ester 
terminated PLGA e-50-50, e-75-25, e-PLL (with catalog numbers of 5050 DLG 7E, 7525 
DLG 7E and 100 DL 7E, respectively) were purchased from SurModics Pharmaceuticals 
(Birmingham, AL).  Silicone rubber RTV 3140 was obtained from Dow Corning 
Corporation (Midland, MI).  Tecoflex polyurethane SG-80A was a gift from Lubrizol 
Advanced Materials (Cleveland, OH).  Bromocresol purple was obtained from Fisher 
Scientific (Pittsburg, PA) and bromothymol blue was obtained from Sigma-Aldrich (St. 
Louis, MO).  Phosphate buffered saline (PBS), pH 7.4, containing 137 mM NaCl, 2.7 
mM KCl, 10 mM sodium phosphate, was used in all experiments.  Tetrahydrofuran 
(THF) was obtained from Fisher Scientific (Pittsburgh, PA) and was distilled over 
sodium and benzophenone prior to use.  All aqueous solutions were prepared with 
deionized water from a Milli-Q system (18 MΩ cm
-1
; Millipore Corp., Billerica, MA).  
Escherichia coli K-12 MG16653 and Staphylococcus aureus ATCC 45330 were 
purchased from American Type Culture Collection.  Luria Bertani (LB) agar and broth 
were products of Fisher Scientific Inc. (Pittsburgh, PA). DBHD/N2O2 was synthesized by 
treating N, N’-dibutyl-1, 6-hexanediamine (DBHD, Aldrich) with NO gas (80 psi, 
Cryogenic Gases (Detroit, MI)) at RT for three days as previously described.
11
 
DBHD/N2O2 and PLGA were stored in a desiccator at -20 °C before use. 
2.2.2 Preparation of NO release films 
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Glass slides (0.9  5 cm) were cleaned by sonicating in acetone, deionized water and 
acetone sequentially and dried before use.  Two hundred mg of a given type of PLGA 
was dissolved in 3 mL THF and 50 mg or 86 mg of DBHD/N2O2 was then added to the 
solution to form a dispersion containing 20 wt% or 30 wt% of the NO donor, 
respectively. The dispersion was then sonicated until a homogeneous dispersion was 
formed.  Twenty five microliters of the dispersion was then cast in an O-ring (o.d.=7 mm) 
on a glass slide to form an NO-release base layer.  The O-ring was then removed and the 
remaining layer was allowed to dry.  This procedure was repeated another three times.  
Then, 100 L of SR solution (160 mg mL
-1
 in THF) was then casted over the NO-release 
PLGA layer as a top coating.  The NO release layer was fully covered by the top coating 
(see Figure 2.1A).  The bilayer film was then dried in air for one day and in vacuum with 
desiccant for two days to remove residual solvent before testing. The diameter of the NO 
release layer was 7 mm.  All the controls were prepared in the same way as the NO 
release films, except PLGA alone or PLGA mixed with DBHD was used as the base 
layer.  In addition, for comparison, SR and polyurethane (PU) were also used to replace 
PLGA as matrices for the underlying layer.   
The thickness of the top coating was optimized by evaluating the leaching of DBHD 
from films containing a base layer of 20 wt % DBHD mixed with a-50-50 PLGA with 
different top coating thicknesses using a Micromass LCT Time-of-Flight mass 
spectrometer.  The solutions for MS spectra were prepared as follows: A solution (sol 1#) 
was prepared containing 5 mL methanol, 0.5 mL H2O and 50 L glacial acetic acid for 
dilution purposes. The MS spectra comparison is shown in Figure 2.2. Firstly, 1 L 
DBHD was dissolved in 1 mL sol 1# to obtain the MS spectra of DBHD, which exhibits 
the peak of [M+H]
+
 at 229.3 as shown in Figure 2.2A. For the leaching test, the films 
with different top coatings were soaked in 2 mL PBS buffer for two days at 37 C and 20 
L soaking buffer was diluted by 1 mL sol 1#.  From the comparison of spectra of 
Figure 2.2B and Figure 2.2C, it is obvious that a thicker coating with 100 L SR is able 
to minimize leaching of DBHD from the film.  Therefore, 100 L SR was chosen for the 
top coating for all the NO release and control films. According to the peak height in the 
mass spectra, the total leaching of DBHD is < 54 mol (<140 mol  cm
-2
).  After two 
days, the leaching of the diamine is < 0.74% of the total DBHD incorporated into the 
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film.  The NO release film should release less DBHD than the control due to the 
replacement of DBHD with DBHD/N2O2.  
 
 
Figure 2.2. MS spectra of A) DBHD; B) soaking buffer for film using 100 L of 20 wt% 
of DBHD mixed with a-50-50 PLGA as base layer and 50 L SR as top coating; C) 
soaking buffer for film using the same base layer and 100 L SR as top coating.  
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Figure 2.3. SEM image of a cross-section of a DBHD/N2O2-PLGA-SR-based NO release 
coating. The film has a two-layer configuration with a base layer of DBHD/N2O2 mixed 
in PLGA and silicone rubber as the top coating.  
 
The thickness of the PLGA-based NO release layer as determined by Scanning 
Electron Microscope (SEM) was 100~130 m and the thickness of the SR top coating 
was 120 m (see Figure 2.3).  SEM images were taken on an Amray FE 1900 Scanning 
Electron Microscope (SEM) at a working distance of 12 mm at 5 kV. The films were 
sputter-coated with gold for 30 s before imaging.   
2.2.3 Evaluation of solution pH and pH changes in films 
Ten microliters of 5 mM solutions of the pH probes (in THF) were added into 300 L 
PBS buffers with pHs ranging from 3 to 8, respectively, in a round bottom 96-well 
microplate, and the image of the twelve wells was recorded to obtain the color chart of 
the two indicators.  Dispersions were then prepared, as indicated in Section 2.2.2., and the 
indicator solutions were added to the NO release or control PLGA dispersions to reach a 
final concentration of 10 mmol kg
-1
.
12
  The colors of the dispersions were compared right 
after the dispersions were prepared.  For in-situ pH assessment, the films were stored in 
pH 7.4 PBS in uncapped scintillation vials at R.T. (23 °C) or 37 C.   The solutions were 
replaced daily and the images of the films in PBS buffer were taken at different time 
points.  
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2.2.4 NO release measurements 
The NO release profiles of the bilayer coatings were measured by purging N2 into 2 
mL PBS buffer solution, pH 7.4, in a glass cell protected from light and monitored using 
a chemiluminescence NO analyzer (NOA) (Sievers 280, Boulder, CO).  The NOA 
calibration curve was obtained by adding nitrite to an acidified potassium iodide solution 
and plotting the integrated signal (ppbs) vs. moles of NO that were introduced into the 
system.
13
  The films were stored as described in Section 2.2.3, and the NO production 
was measured by the NOA and the NO fluxes at different time points were calculated 
using the calibration curve.  The flux values were reported as average  standard 
deviation calculated from the fluxes of two films with the same formulation. 
2.2.5 In vitro antimicrobial test  
Overnight LB (Luria Bertani) broth grown bacterial cultures were washed with 1PBS 
buffer three times, and resuspended in 1PBS buffer to make a final cell concentration at 
~10
8 
CFU/mL.  Each NO release or control film was placed into a Corning 15-mL tube 
with 2 mL of the washed bacterial culture solution.  The tube was incubated at 37 C for 
2 h or 24 h while horizontally shaking at 150 rpm.  After incubation, the films were 
removed aseptically and the bacterial culture was serially diluted 10-fold in 1PBS buffer 
and 50 µL of each dilution was plated onto an LB agar plate for viable bacterial counting.  
All the experiments were conducted in duplicate. 
2.2.6 In vitro antibiofilm testing  
A CDC flow bioreactor (Biosurface Technologies, Bozeman, MT) was used for the 
antibiofilm testing.  The CDC bioreactor with its coupon holders was autoclaved before 
use.  Coated slides were mounted on the coupon holders and the reactor was 
supplemented with 10% LB medium by a peristaltic pump with a continuous flow rate of 
100 ml/h.  Overnight bacterial cultures were diluted 1:100 and inoculated into the glass 
vessel of CDC reactor aseptically.  The liquid growth medium was circulated through the 
vessel and shear force was generated by a magnetic stir bar rotated by a magnetic stir 
plate.  Biofilms developed on the surface of coated slides were completely immersed into 
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the circulating culture.  The CDC bioreactor was set up on the bench at room temperature 
(23 °C) or in an incubator at 37 °C. 
After a 7 d incubation, coated slides were aseptically removed and individual slides 
were transferred to a petri dish for further staining with LIVE/DEAD® BacLight™ 
Bacterial Viability kit (L7012, Invitrogen, Carlsbad, CA) according to instructions in the 
reagent manual. Fluorescent images were acquired with a fluorescence microscope 
(Olympus 1X71, Center Valley, PA) equipped with Fluorescence Illumination System 
(X-Cite 120, EXFO) and filters for SYTO-9 (ex. 488 nm/em. 520 nm) and Propidium 
Iodide (ex. 535 nm/em. 617 nm) fluorescence.  Images were obtained using an oil 
immersion 60 × objective lens.  The slides were also examined under an Olympus 
FluoviewTM FV1000 confocal microscope (Olympus, Markham. Ontario) with Melles 
Griot Laser supply, detectors and appropriate filter sets.  Three different spots on the NO 
release area of each film were randomly chosen to obtain both 2D and 3D images.  
Simulated 3D images were reconstructed using the Amira software package (Amira, San 
Diego, CA) and biofilm biomass values were quantified using the COMSTAT software 
(version 1) 
14
 with the threshold setting as 25.  
2.3 Results and Discussion 
2.3.1 Selecting pH-sensitive probes for film pH measurement 
It is reported that at a given temperature, the decomposition of intramolecular 
zwitterionic diazeniumdiolates such as DBHD/N2O2 is pH dependent. The NO release 
rate decreases as the environmental pH increases.
11
  Therefore, to understand and control 
the release profile of DBHD/N2O2-based NO release coatings, it is important to develop a 
method to monitor the pH change in the PLGA film.  
Previously, our group demonstrated that the pH change of a DBHD/N2O2-based NO 
release PVC films could be evaluated by incorporating a chromoionophore and 
comparing the UV-Vis spectra of the film at different time points.
11
  This method, 
however, suffers from the interferences from the light scattering signal due to the 
insolubility of DBHD/N2O2.  Recently, the Schwendeman group developed a confocal 
flurescence microscope imaging method to directly quantify the microclimate pH 
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distribution in PLGA microspheres using a pH-sensitive probe.
15
  As alternatives to 
fluorescence probes, pH indicators offer a facile, inexpensive and more convenient way 
to qualitatively visualize the pH changes.
16
 
To effectively evaluate the film pH change within the NO release coating over a long 
period of time, the pH probe needs to be sensitive enough to change color during the NO 
release and the PLGA hydrolysis process.  As shown in Figure 2.1B, within the NO 
release film, DBHD/N2O2 releases NO through a proton driven mechanism and produces 
the diamine DBHD, which will further increase the film pH.  In contrast, the hydrolysis 
of PLGA that takes place simultaneously will cause a decrease in the film pH.  Therefore, 
it is important for the indicator to change color according to these changes to visualize 
the acidic or basic environment created by the reactions within the polymeric coating.  
Furthermore, the amount of the pH indicator should also be well-controlled.  While it is 
not sensitive enough to reflect a color change with too little pH probes incorporated, too 
much probe will also compete with the NO donor for available protons within the 
membrane and change the NO release profile.  
Based on all of the above requirements, two sulfonphathaleins, bromocresol purple 
(BP) and bromothymol blue (BB), were selected as the pH-sensitive probes and added 
into the solutions or dispersions in a reported ratio
12
 to evaluate their suitability as film 
pH indicators.  As shown in the color chart in Figure 2.4, in PBS buffers with pH ranging 
from 3-8, the color of bromocresol purple (BP) changes from yellow to purple with the 
transition pH range of 5-6.  For bromothymol blue (BB), on the other hand, the color 
changes from yellow to green and blue with a higher transition pH range of 6-8.  The 
indicators were then added into different solutions or dispersions and the colors obtained 
were compared in Figure 2.4. First of all, a solution of 20% diamine DBHD in PLGA 
was used to represent an extreme case, in which all the NO was released from the NO 
donor DBHD/N2O2 while neglecting the hydrolysis of PLGA.  In the real case, the film 
pH should be lower.  Therefore, a good probe should at least be able to distinguish the 
difference between a mixture containing 20% of the NO donor DBHD/N2O2 in PLGA 
and a solution of 20% DBHD in PLGA.   
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Figure 2.4. Comparison of color changes of bromothymol blue (BB) and bromocresol 
purple (BP) in different solutions or dispersions including pure PLGA, DBHD/N2O2, 20 
wt% DBHD/N2O2 mixed in PLGA, 20 wt% DBHD in PLGA and silicone rubber THF 
solution (The concentration for all polymer solution is 200 mg/3 mL). a-50:50 lactide: 
glycolide PLGA is used for all the experiment. The indicator concentration is 10 mmol 
kg
-1
.  The colors of the solutions were compared rightly after the solutions were prepared. 
The color chart above indicates the variation of indicator colors with pH in PBS buffer. 
 
 
As shown in Figure 2.4, for each of the indicators, a distinguishable color difference 
between the two mixtures is observed, indicating a much more basic environment once 
the NO is totally released.  In addition, for both indicators, a suspension of DBHD/N2O2 
exhibits a transition color totally different from the above two mixtures, indicating the 
sensitivity of both pH probes.  It is also clear from the color difference that PLGA is the 
most acidic solution as previously reported.
15
  Meanwhile, it is difficult to differentiate 
the acidity of PLGA and SR solutions due to the narrow transition pH range of both pH 
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probes. However, this does not affect their capability to be potentially used to indicate 
film pH changes in the NO release coatings.  
2.3.2 Correlating film pH with NO release profile 
As reported previously, the release of NO from DBHD/N2O2 will produce the diamine 
DBHD and further raise the film pH and decrease the NO release rate for 
diazeniumdiolates.  Without any additives such as borate or PLGA to adjust the pH in the 
film, the NO fluxes of the NO release coatings are low and their lifetimes are short
10, 11
.  
Recently, our group demonstrated that PLGA can be used as a non-toxic alternative to the 
toxic potassium tetrakis(4-chlorophenyl)borate (KTpClPB), which is also an inhibitor to 
glucose oxidase, to promote the NO release of DBHD/N2O2 in a two-layered NO release 
coating
10
.  However, since no study has been done to correlate the pH change of the films 
with the NO release profile, our understanding of this system is incomplete.  
To further understand the system and to better control the NO release profile of this 
type of film, an NO release coating with a similar configuration was prepared.  As shown 
in Figure 2.1, the coating used in this experiment has a two-layered configuration. In the 
inner layer, DBHD/N2O2 is embedded in the PLGA matrix and releases NO when water 
penetrates in.  The outer layer is a SR top coating, which is used to protect the inner 
layer, extend the NO release time and prevent leaching of toxic species from the film into 
the surrounding solution.  It is important that the SR top coating fully covers the entire 
NO release layer including the edges. Meanwhile, since a thin top coating will enhance 
the leaching of toxic diamine DBHD species and a thick top coating will impede the 
water uptake of the film thus the NO release, the thickness of the top coating should be 
optimized as indicated in the Experimental Section 2.2.2.  
PLGA has been widely used in biomedical areas recently not only due to its 
biocompatibility, but also because of its controlled degradation achieved by the nature of 
innate acid or ester end groups as well as the lactide to glycolide ratio in the polymer 
chain.
17
  Since the NO release of diazeniumdiolates is dependent on pH and 
temperature,
11
  it is of interest to study the release profiles of the NO release films 
containing PLGA with different hydrolysis rates at different temperatures.  Further, if the 
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lifetime of the NO release coatings can be extended to a week or longer, they can serve as 
models to study the antibiofilm effects of NO release coatings.  
 
 
Figure 2.5. NO release profiles of NO release films with a base layer containing A) 20 
wt% DBHD/N2O2 in a-50-50 and or e-50-50 at RT; B) 30 wt% DBHD/N2O2 in a-50-50, 
e-50-50, e-75-25 or e-PLL at 37 °C. The NO flux was recorded on a chemiluminescence 
NO analyzer (NOA). The fluxes presented are the average of two films (n=2). *, P<0.05 
(the fluxes of a-50-50-based NO release films are significantly different from the fluxes 
of e-50-50-based films). 
 
 
Therefore, the NO release profile and film pH change of two NO release coatings with 
20% DBHD/N2O2 incorporated into two types of PLGA matrixes at RT (23 °C) were 
examined first.  Both PLGAs had a lactide to glycolide ratio of 50:50, but the end group 
was acid and ester, respectively.  The NO release profiles of the films were monitored 
daily until the depletion of the NO donor and the results are shown in Figure 2.5A.  As 
shown in Figure 2.5A, while the film with the acid-capped PLGA (a-50-50) exhibits a 
steadily decreasing NO flux over time, there are no significant variations in the daily NO 
flux of the ester-capped PLGA (e-50-50)-based film except on the second and last day of 
the NO release period.  Although the daily NO flux of the e-50-50-based film is lower 
compared to the film with the a-50-50, the NO release lifetime is extended from ten days 
to a fifteen-day period.   
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Figure 2.6. A) comparison of color changes of bromothymol blue (BB) or bromocresol 
purple (BP) doped NO release films containing a base layer of 20 wt% DBHD/N2O2 in a-
50-50 and or e-50-50 at RT; B) comparison of color changes of bromothymol blue (BB) 
doped NO release films containing a base layer of 30 wt% DBHD/N2O2 in a-50-50, e-50-
50, e-75-25 or e-PLL at 37 °C for 10d. D2, D3, D5, D7, D8, D10 represent day 2, day3, 
day 5, day 7, day 8 and day 10, respectively. 
 
 
To further explain the NO release pattern, the two pH sensitive probes were further 
incorporated into the polymeric films to evaluate the pH changes in the coating over time.  
As shown in Figure 2.6A, as soon as the films are in contact with solution, both probes 
indicate a more basic environment for the e-50-50-based film due to the difference in 
their end groups.  Within 3 h of NO release, an increase of the film pH has already been 
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observed for both films and it gets more obvious after a 24 h period.  After the second 
day, however, due to the hydrolysis of PLGA, a gradual decrease in the film pH begins to 
be observed for the a-50-50-based film (Figure 2.6A-a and Figure 2.6A-c).  The e-50-
50, on the other hand, degrades much more slowly in the film, resulting in a much less 
obvious color change of the probe incorporated within the coating (Figure 2.6A-b and 
Figure 2.6A-d).  
 
PLGA (ester-
capped) 
Lactide:glycolide Lactide 
residual 
wt% 
Glycolide 
residual 
wt% 
Viscosity 
dL/g 
Molecular 
weight 
(Mw) 
5050 DLG 7E 50:50 1.0  0.2 0.80 132 KDa 
7525 DLG 7E 75:25 1.5 0.1 0.71 114 KDa 
100 DL 7E 100:0 3.1 0 0.70 106 KDa 
 
Table 2.1. Information of ester-terminated PLGAs provided by the vendor. 
 
Based on the above observations, a mechanism is proposed to further explain the 
difference in release profiles for the two NO release coatings.  As shown in Figure 2.1, 
as soon as the NO release coating is in contact with solution, when water penetrates the 
SR outer layer and permeates into PLGA matrix, the carboxyl end groups and hydrolysis 
products of residual monomers present in the matrix will donate protons to the NO 
donors to release NO through a proton-driven mechanism.  At a given temperature, the 
NO flux is highly dependent on the pH of the film, which is further related with the end 
group type and monomer residue ratio of the PLGA matrix. Therefore, the a-50-50 matrix 
shows a much higher initial NO flux compared to the e-50-50 with a limited ratio of 
monomer residues (see Table 2.1) to promote the initial NO release.  Once NO is 
released, the diamine DBHD will remain in the film and form ammonium salts with the 
carboxyl groups in the PLGA matrix and this process will further facilitate the hydrolysis 
of PLGA to produce more protons and thus promote the NO release.  However, even at a 
given temperature, it is still difficult to predict the NO flux at this stage because it is 
influenced by multiple factors including the water uptake of the coating, the NO donor 
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amount and the hydrolysis rate of PLGA within the films.  For example, the highest NO 
flux for the e-50-50-based films is observed on the second day even though the coating 
pH is higher compared to the first day.  This might due to either the hydrolysis of e-50-50 
that provides more protons that are quickly consumed by the NO donor or the increased 
water uptake of the film on the second day.  Due to its fast hydrolysis rate, the gradually 
decreased daily NO flux observed for the a-50-50-based coating is most likely due to the 
gradual depletion of NO donors within the film.  The steady daily NO flux for the e-50-
50-based coating, on the other hand, is most likely results from the slow hydrolysis rate 
of the PLGA matrix that further stabilizes the pH within the film.  
The RT experimental results indicate that the hydrolysis rate of PLGA can be used to 
control the release profile of the NO release coatings.  While PLGA with fast hydrolysis 
rate creates high NO flux, PLGA with slower hydrolysis rate can extend the NO release 
lifetime.  At 37 °C, both the NO release rate of diazeniumdiolates and the hydrolysis rate 
of PLGA will be elevated.  Since it is reported that a slower hydrolysis rate can be 
achieved by increasing the lactide ratio in the PLGA polymer chains,
17
 e-PLGAs with a 
lactide to glycolide ratio of 75:25 (e-75-25) and poly(lactic acid) (e-PLL) were also used 
to prepare the NO release coatings used at 37 °C.  Figure 2.5B shows the NO release 
profiles for four films containing 30 wt% DBHD/N2O2 doped into a-50-50, e-50-50, e-
75-25 or e-PLL at 37 °C.  The NO release profiles are consistent with the prediction from 
the RT experimental results.  The films are able to release NO for three, five, eight and 
ten days for a-50-50, e-50-50, e-75-25 or e-PLL, respectively.  The slower the PLGA 
hydrolysis rate, the longer the NO release lasts.  Due to the introduction of slower 
hydrolyzed PLGAs, bromothymol blue (BB), with a higher transition pH range, was used 
to evaluate the film pH change for the four coatings at 37 °C.  As shown in Figure 2.6B, 
similar to the RT observations, the release of NO firstly increases the film pH and the 
further hydrolysis of PLGA provides additional protons to the NO donors as well as 
lowers the film pH.  From these comparisons, it is obvious that the hydrolysis rates of 
PLGAs are different within the coatings.  While for the a-50-50 (Figure 2.6B-a), the 
hydrolysis of PLGA has already created a very acidic environment on the third day that 
contributes to the depletion of all the NO donors, the film pH of the e-PLL coating 
(Figure 2.6B-d), in contrast, is elevated due to the production of DBHD and remains 
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almost neutral for ten days due to the slow hydrolysis of the PLL matrix.  For e-50-50 
and e-75-25, the hydrolysis of PLGA causes an apparent color change, indicating an 
acidic environment on the fifth (Figure 2.6B-c) and seventh day (Figure 2.6B-d), 
respectively.   
The initial NO flux at a given temperature, however, is not related to the hydrolysis 
rate of the polymer, but the initial film pH.  The acid capped PLGA, a-50-50, should be 
the one that creates the most acidic environment. For the ester-capped PLGAs, as listed in 
Table 2.1, the monomer residue percentages are in the order of e-PLL > e-75-25 > e-50-
50.  Therefore, the initial pH of the films are in the order of a-50-50 < e-PLL < e-75-25 < 
e-50-50, which is further supported visually by comparing the film colors at 0 min (film 
pH a<d<c<b shown in Figure 2.6B).  The order of the initial NO flux of the four films, as 
shown in Figure 2.5B (D1), is consistent with the film acidity order, which further 
supports that at a given temperature, the initial NO flux is highly dependent on the film 
pH.  Thus, it is also possible to control the initial NO flux of the films by controlling the 
end groups and monomer residues within the PLGA polymer matrix.  Therefore, PLGA 
acts as not only a promoter, but also a controller of the NO release within the coatings.  
The NO release profiles and film pH of films containing other matrices such as SR and 
PU instead of PLGA in the base layer were also studied and the results are shown in 
Figure 2.7.  The difference between the PLGA matrix and SR or PU lies in that the other 
two matrices lack the initial acid residues or the capability to hydrolyze to produce 
protons for the NO donor.  Therefore, when the control films with a base layer of 30 wt% 
DBHD/N2O2 doped in SR and PU are placed into 37 °C PBS buffer, hardly any NO 
release is observed compared to films with various PLGAs incorporated (Figure 2.7A).  
Only a slight pH increase in the SR or PU-based film is observed over a one week period 
due to the production of DBHD, as shown in Figure 2.7B.  This is a further proof of the 
important role of PLGA as both an NO release promoter and controller.  
 
 
 
 
 
38 
 
 
Figure 2.7. A) Initial NO release profiles of films with different polymers incorporated; 
B) pH changes of polyurethane and silicone rubber-based NO release films over a one 
week period. The control films are prepared in the same way as the PLGA-based NO 
release films except that SR or PU was used as the polymer matrix for the base layer. 
Bromothymol blue (BB) was used as the pH indicator. 
 
 
2.3.3 Antibiofilm properties of NO release films 
Before any antibiofilm testing, an in vitro antimicrobial test was used to compare the 
influence of the NO release film and a series of control films on planktonic bacterial 
cells.  The aim of the test was to study the “matrix” effect and further evaluate the 
leaching of toxic diamine DBHD.  An NO release film with 20 wt% DBHD/N2O2 mixed 
with a-50-50 PLGA as the inner layer was chosen because PLGA with the fastest 
hydrolysis rate is most likely to have the above problems.  Therefore, two controls were 
used in this test including a film with only PLGA (PLGA/SR) and a film with PLGA 
doped with 20 wt% diamine DBHD (20% DBHD) as the inner layer.   
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Figure 2.8. The antimicrobial killing effects of NO release films with a base layer of 20 
wt% DBHD/N2O2 doped in a-50-50, control films with a base layer of a-50-50, 20 wt% 
DBHD doped in a-50-50 and control film with only SR top coating on A) S. aureus; B) 
E. coli after 2 h and 24 h incubation at 37 °C in 10
8
 CFU/mL bacterial suspension. 
 
 
As shown in Figure 2.8, when the NO release films and control films were placed into 
PBS buffer containing 10
8
 CFU/mL S. aureus (Figure 2.8A) or E. coli (Figure 2.8B) at 
37 °C for 2 h, the NO release films showed ~1 log killing (i.e., the number of viable cells 
was reduced from ~1.810
8
 to ~3.710
7
 CFU/mL for S. aureus and ~2.210
8
 to ~510
7
 
CFU/mL for E. coli) compared to the controls that almost showed no changes.  After 24 h 
exposure, with a continuous production of NO as the antimicrobial agent, 3 logs of killing 
of both S. aureus and E. coli (i.e., the number of viable cells was reduced from ~1.810
8
 
to ~3.510
5
 CFU/mL for S. aureus and for ~2.210
8
 to ~3.110
5
 CFU/mL for E. coli) 
were observed.  Compared to a control film that contains only a SR layer that exhibits 
almost no killing effect after 24 h exposure to bacterial suspension, the PLGA/SR or 20% 
DBHD control film showed ~1 log killing effect for both bacterial strains resulting from 
the “matrix” killing effect.  However, this is much less than the NO release coatings, 
indicating NO, as reported, is a potent antimicrobial agent for both gram-positive S. 
aureus and gram-negative E. coli.
1
  If there is a significant leaching of the diamine 
DBHD, the 20% DBHD control film should exhibit a much greater killing effect 
compared to either the NO release film or the PLGA/SR control.  However, since both 
controls exhibit almost identical effect on planktonic bacterial cells, the minimized 
leaching of toxic DBHD from films with current configuration is further demonstrated.  
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When the same test was performed at RT (23 °C), however, none of the films exhibited 
any killing effect after 24 h incubation (data not shown).  Thus indicates that higher 
temperature leads to faster hydrolysis of PLGA and enhanced release of NO, which also 
contributes to the “matrix” effect and antimicrobial effects of the NO release films.     
Although the antibiofilm properties of NO release coatings have been proven by both 
in vitro and in vivo studies, there have been few examples that studied the influence of 
different NO release profiles on the antibiofim properties of NO release coatings over a 
time scale that is long enough to form a mature biofilm.  For example, the Schoenfisch 
group has evaluated and demonstrated the antibiofilm property of NO release xerogel 
coatings against S. aureus in a subcutaneous animal model after eight days of 
implantation.
18
  However, considering around 90% of the NO was released from their 
coating over the initial 24 h,
18
 it will be difficult to study the influence of NO release 
profiles on the antibiofilm property of this type of  film over an equivalent time scale.  
Similarly, although in vitro studies under both stagnant and dynamic conditions have 
shown that NO release catheters are able to prevent biofilm formation by E. coli, the NO 
release profile of the catheter is untunable and exhibits an initial “burst” of NO release.
19
  
Considering the complexity and time-scale of formation of a mature biofilm, the 
DBHD/N2O2 and PLGA-based NO release coating, with a tunable NO release profile 
over more than one week period offers an ideal model to study the influence of different 
NO release profiles on the antibiofilm properties of the coatings.    
A CDC biofilm reactor was chosen as a tool for the study of the antibiofilm properties 
of the prepared NO release coatings because it is able to provide both shear forces and 
renewable nutrient sources that mimic an in vivo environment
7
 and the film is 
continuously exposed to bacterial culture.  It is also proven by statistical assessment to be 
a reliable tool for growing biofilms with repeatable results.
20
  Compared to previously 
reported studies of microbial adhesion on NO release coatings in flowing systems for a 
short period of time with
19
 or without
6, 8
 nutrient sources, a seven-day biofilm test in a 
CDC biofilm reactor will better mimic a natural environment.  Furthermore, the study of 
the antibiofilm properties of NO release coatings with tunable NO release profiles in a 
CDC biofilm reactor at different temperatures can provide further information to better 
utilize the NO release coatings for antibiofilm applications.  
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Figure 2.9. Representative fluorescent micrographs showing comparison of surfaces of 
NO release and control films after incubation at RT (23 ºC) for seven days in a CDC 
biofilm reactor containing S. aureus or E. coli. The NO release films containing a base 
layer of 20 wt% DBHD/N2O2 mixed with a-50-50 or e-50-50 PLGA matrix, and the NO 
release profile of the films are shown in Figure 2.5A. The controls include two films 
with base layers of a-50-50 PLGA or a-50-50 PLGA mixed with 20 wt% DBHD and a 
film with only a SR layer. Bacterial cells were stained with Bacterial LIVE/DEAD 
staining dyes and viable cells shown as green fluorescent dots while dead or membrane 
damaged cells shown as red fluorescence dots in the images. 
 
Therefore, the NO release films and corresponding controls were first incubated in a 
CDC biofilm reactor at RT (23 °C) with gram-positive S. aureus or gram-negative E. coli 
cultures for seven days.  On the eighth day, the films were taken out of the reactor and 
stained with bacterial LIVE/DEAD dyes to visualize the growth of biofilm on different 
surfaces.  The NO release profiles of the films are shown in Figure 2.5, and Figure 2.9 
shows the representative fluorescent micrographs of the surfaces of the NO release and 
control films after the antibiofilm test in the CDC reactor.  As shown in Figure 2.9, for 
all the control films including PLGA/SR, 20% DBHD and SR, the surfaces are fully 
colonized by mostly viable S. aureus or E. coli cells (shown as green dots).  In contrast, 
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NO release films containing a base layer of 20 wt% DBHD/N2O2 doped in either a-50-50 
or e-50-50 PLGA exhibit clean surfaces.  Compared to the a-50-50 PLGA-based NO 
release film that barely exhibit any observable bacterial cells on the surface, a small 
amount of bacterial cells are still observable on the e-50-50 PLGA-based film surface for 
both S. aureus and E. coli.  This might be attributed to the differences in the daily NO 
flux of the two films (see Figure 2.5A) with the film having a higher NO flux exhibiting 
a better antibiofilm effect.  To gain a better view and quantification of biofilm structure 
and biomass, 3D images were reconstructed based on the confocal images.  The 3D 
images representing S. aureus biofilm formation on different surfaces at RT are shown in 
Figure 2.10A and the quantitative analysis data are listed in Table 2.2.  Similar to the 
fluorescent micrographs, the 3D images also confirm the significant antibiofilm effect of 
the NO release coatings.  As shown in Figure 2.10A, thick, dense and carpet-like 
biofilms containing mostly living S. aureus cells are developed on the surfaces of all the 
control films with some variations in the biofilm structures between the SR surface and 
the other two controls.  The surface of the NO release films, on the other hand, barely has 
any bacterial cell attachment, indicating significant antibiofilm effect due to the NO 
release from the film.  The biofilm biomass values quantified from the 3D images are 
listed in Table 2.2.  Even for the e-50-50-based NO release film, with a less effective 
antibiofilm effect, more than 99.9% reduction of the biofilm biomass is obtained and 
similar results are also obtained for E. coli, as listed in Table 2.2.  Interestingly, while 
neither of the NO release films exhibit observable antimicrobial effect in the 
antimicrobial test at RT, the antibiofilm property of each is significant, even for the e-50-
50 PLGA-based NO release film with a relatively low NO flux.  Viable cell counts before 
and after the antibiofilm test indicated that after one week growth in the medium, the 
bacterial concentration is ~100 times higher than the initial concentration (i.e., the viable 
cell counts increases from ~110
6 
CFU/mL to ~2.710
8
 CFU/mL for both S. aureus and 
E. coli).  Due to the short lifetime of NO, it is impossible for it to diffuse far enough to 
kill all the planktonic bacterial cells in solution, especially if there’s limited amount of 
NO production.  This might contribute to the low antimicrobial property for the NO 
release films at RT in the antimicrobial tests.  However, since it is still possible for NO to 
interact with planktonic bacterial cells that are close enough to the coating surface, the 
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NO release coating is able to create a “bacterial inhibition zone” as previously reported,
19
 
which contributes to the observed antibiofilm effect for the NO release coatings.  
Furthermore, low levels of NO has been reported to induce the dispersal of diverse 
single-species and multi-species biofilms of gram-positive and gram-negative bacteria 
through signaling.
2, 21
  Since the experimental results have also indicated the NO release 
coating with a low daily NO flux (Figure 2.5A, e-50-50) is able to prevent biofilm 
formation, the observed antibiofilm effect of NO release coating, might also arise from 
NO’s potent biofilm dispersal effect. 
 
Films 
S. aureus E.coli 
Biomass/m
3/
m
2
 Biomass/m
3/
m
2
 
NO release 
a-50-50 00 0±0 
e-50-50 1.5±0.310
-3
 1.8±0.810
-3
 
Control 
PLGA/SR 5.2±0.7 4.9±0.5 
20% DBHD 4.1±0.6 5.7±2.4 
SR 3.6±0.4 4.4±0.6 
 
Table 2.2. Biofilm biomass in S. aureus and E. coli biofilm on PLGA-based bilayer films 
in CDC biofilm reactor at RT. Average values with standard deviations for n= 3 shown in 
the brackets were calculated from COMSTAT image analysis on CLSM images. 
 
 
Films 
S. aureus E.coli 
Biomass/m
3/
m
2
 Biomass/m
3/
m
2
 
NO 
release 
a-50-50 8.6±1.010
-3
 4.0±1.210
-3
 
e-50-50 8.3±3.610
-3
 1.3±0.510
-3
 
e-75-25 9.2±7.510
-3
 7.0±4.810
-4
 
e-PLL 9.4±6.010
-4
 1.6±0.610
-4
 
Control 
PLGA/SR 1.4±1.610
-2
 4.0±1.810
-1
 
30% 
DBHD 
5.9±2.510
-2
 4.0±1.010
-1
 
SR 5.9±0.510
-2
 6.0±1.410
-1
 
 
Table 2.3. Biofilm biomass in S. aureus and E. coli biofilm on PLGA- or PLL-based 
bilayer films in CDC bioreactor at 37 C. Average values with the standard deviations for 
n = 3 shown in the brackets were calculated from COMSTAT image analysis on CLSM 
images. 
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Figure 2.10. Three-dimensional images of S. aureus biofilm formed A) at RT on NO 
release films with a base layer of 20 wt% DBHD/N2O2 doped in a-50-50 or e-50-50 
PLGA and control films with a base layer of a-50-50, a-50-50 mixed with 20 wt% DBHD 
or a control film with only a silicone rubber top coating. The dimension of the films are 
142 108 15 m;  B) at 37 °C on NO release film with a base layer of 30 wt% 
DBHD/N2O2 doped in a-50-50, e-50-50, e-75-25 or e-PLL PLGA matrix and control film 
with a base layer of a-50-50, a-50-50 mixed with 30 wt% DBHD and a film with only a 
silicone rubber top coating after incubation in a CDC biofilm reactor after seven days. 
The dimension of the films are 142 108  9 m. Bacterial cells were stained with 
Bacterial LIVE/DEAD staining dyes and viable cells shown as green fluorescent dots 
while dead or membrane damaged cells shown as red fluorescence dots in the images. 
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Figure 2.11. Representative fluorescent micrographs showing comparison of surfaces of 
NO release and control films after incubation for seven days at 37 ºC in a CDC biofilm 
reactor containing S. aureus or E. coli. The NO release films containing a base layer of 
30 wt% DBHD/N2O2 mixed with a-50-50, e-50-50, e-75-25 or e-PLL PLGA matrix, and 
the NO release profile of the films are shown in Figure 2.5B. The controls include two 
films with base layers of a-50-50 PLGA or a-50-50 PLGA mixed with 30 wt% DBHD 
and a film with only a SR layer. Bacterial cells were stained with Bacterial LIVE/DEAD 
staining dyes and viable cells shown as green fluorescent dots while dead or membrane 
damaged cells are shown as red fluorescence dots in the images. 
 
 
The antibiofilm properties of NO release coatings with different NO release profiles 
(shown in Figure 2.5B) were further evaluated at the physiological temperature of 37 °C 
and the representative fluorescent micrographs of bacterial adhesion on different surfaces 
after the antibiofilm test are shown in Figure 2.11.  Compared to the SR surface that is 
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fully colonized by bacterial cells after the antibiofilm test at RT (see Figure 2.9), the 
biofilm formation on the same type of surface for either S. aureus or E. coli (Figure 2.11) 
is less obvious at 37 °C.  This is similar to the observations in previous reports where S. 
aureus
22, 23
 or E. coli
24
 formed optimal biofilm coverage at lower temperature compared 
to physiological temperature.  Different from the SR surface, the PLGA/SR and 30% 
DBHD control film surfaces exhibit more dead cells compared to viable cells, indicating 
a “matrix” killing effect occurs at 37 °C.  However, for both S. aureus and E. coli, the 
NO release coating surfaces are much less colonized compared to the controls, indicating 
much better antibiofilm effect results via the NO released from the coatings.  This is 
consistent with the observation in the previously described solution-based antimicrobial 
tests at 37 °C, where the NO release coatings exhibit much better killing effect on 
planktonic bacterial cells compared to the two controls that also exhibit a small “matrix” 
killing effect (Figure 2.8).  In addition, high temperature might also increase the 
permeability of the cell membrane, which can also contribute to greater dead or 
membrane damaged cells observed on the surfaces.  
The antibiofilm effects of different NO release coatings, however, vary with bacterial 
strains and the NO release profiles.  A difference was also observed in the viable cell 
counts after one week incubation at 37 °C for different bacterial strains in the CDC 
biofilm reactor.  While the viable cell counts for S. aureus increased from ~1.8 10
6
 to ~ 
8.610
9
 CFU/mL, the growth of E. coli was slower (i.e., the viable cell counts increased 
from 1.6 10
6
 to 4.6 10
8
 CFU/mL). Therefore, the antibiofilm properties of the NO 
release films on different bacterial strains were compared separately.  For S. aureus, with 
a faster growth rate, although the formation of S. aureus biofilms on all the control films 
can be clearly observed as shown (see Figure 2.11), only a few dead or membrane 
damaged bacterial cells are observed on the surfaces of NO release films with different 
NO release profiles.  The antibiofilm effects are almost identical for all the NO release 
films regardless of the differences in the lifetime of the films.  However, the e-PLL-based 
NO release film with the longest NO release lifetime (Figure 2.5B) exhibits a cleaner 
surface.  The 3D images for S. aureus biofilm formation on different surfaces are shown 
in Figure 2.10B and the biomass values are quantified and listed in Table 2.3.  Similar to 
the observations from the 2D images, the 3D images indicate that at RT, a denser and 
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more evenly distributed S. aureus biofilm is formed on a SR surface compared to 37 °C.  
The calculated S. aureus biofilm biomass values listed in Table 2.3 for different surfaces 
further support the antibiofilm properties of NO release coatings.  With a biofilm biomass 
reduction of ~ 98.4% compared to a silicone rubber control, the e-PLL-based NO release 
coating that is able to release NO for the longest time period is the most effective coating 
to prevent S. aureus biofilm formation at 37 °C.  In contrast, a-50-50, e-50-50 and e-75-
25 PLGA-based coatings all exhibit ~85% biofilm reduction despite the fact that the 
lifetime of films varies from three to eight days.  One possible explanation for the better 
antibiofilm effect observed for e-PLL compared to the e-75-25-based NO release coating 
might be that there was a time lag between the evaluation of the NO flux and the removal 
of the film from the CDC reactor on the eighth day, so the e-75-25 PLGA-based NO 
release coating might stop releasing NO before its removal, which was not the case for 
the e-PLL-based coating. 
When E. coli is used instead of S. aureus, the influences of different NO release 
profiles on the antibiofilm properties of the NO release films at 37 °C are more clearly 
observed.  As shown in Figure 2.11, for all the control films, a high percentage of the 
surface is colonized by E. coli cell clusters.  Compared to a SR surface where both viable 
and dead cells can be observed, most of the E. coli cells that are attached on either the 
PLGA or the 30% DBHD control films are dead or membrane damaged cells due to the 
“matrix” effect.  Since the attachment of dead bacterial cells can trigger immune 
responses and inflammation,
25
 an “ideal” antibiofilm coating should be able to prevent 
the attachment of both living and dead bacterial cells.
26
  Compared to the controls, the 
NO release coatings exhibit different extents of antibiofilm properties due to their 
different NO release profiles (Figure 2.5B).  It is obvious, however, that the NO release 
coatings with a longer lifetime exhibit a cleaner surface (Figure 2.11) and this effect is 
further supported by the E. coli biofilm biomass values listed in Table 2.3, which 
indicate the longer the NO release, the lower the E. coli biofilm biomass value.  In 
particular, the e-PLL-based NO release coating was able to reduce the biofilm biomass by 
~ 99.9%.  However, for films with all the other PLGA, > 99% biofilm reduction was 
observed.  Therefore, the combined DBHD/N2O2 and PLGA-based NO release coatings, 
especially those can release NO for a long period, are expected to be potential candidates 
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as antibiofilm coatings for indwelling devices.  Needless to say, the current study is still 
limited because the one week antibiofilm test and ten day NO release at 37 °C are not 
long enough to meet the requirements for all possible indewelling devices.  However, 
since our preliminary study indicated that the lifetime of the NO release coating could be 
extended by increasing the thickness of the NO release layer (data not shown), future 
work will focus on utilizing this type of coating with extended lifetime in animal models 
to evaluate the feasibility of applying such films as antibiofilm coatings for indwelling 
devices. 
2.4 Conclusions 
Nitric oxide release coatings with a bilayer configuration using DBHD/N2O2 doped 
within various PLGA materials were fabricated.  By comparing the NO release profiles 
and film pH changes using PLGAs with different hydrolysis rates, it was shown that the 
specific chemical formulation of the PLGA used plays an important role as both a pH 
promoter and controller in the NO release mechanism.  The new films with tunable NO 
release profiles were proven to prevent S. aureus and E. coli biofilm formation in a CDC 
flow bioreactor using a 7 d antibiofilm test.  The proposed coatings are thus expected to 
be potentially applied on short-term indwelling devices such as catheters to prevent 
thrombus formation and bacterial infection issues and future work will focus on further 
extending the NO release lifetimes of the coatings and conducting appropriate in vivo 
studies. 
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Chapter 3 Carboxyl-Ebselen-Based Layer-by-Layer Films as Potential 
Antithrombotic and Antimicrobial Coatings 
 
3.1 Introduction 
Nitric oxide release coatings have limited lifetimes due to their limited NO reservoirs 
that can be incorporated into the polymeric matrices and an attractive alternative is to use 
NO generation coatings, which are a group of catalytic coatings that are capable of 
generating NO from endogenous RSNOs.  As described in Chapter 1, the toxicity issues 
of aliphatic organoselenium species have limited their application in developing NO 
generation and antimicrobial coatings and the RSNO decomposition catalytic activity of 
aromatic selenium species, such as ebselen (Figure 3.1A) and its derivatives with low 
toxicity have not been studied in detail to date.  
 
 
 
Figure 3.1. Structures of different aromatic organoselenium species. 
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In this chapter, the NO generating catalytic activity of different organoselenium 
species for RSNO decomposition is studied and compared.  By covalently attaching 
carboxyl-ebselen (C-ebselen, Figure 3.1B) to polyethylenimine (PEI), ebselen-PEI (e-
PEI, Figure. 3.1C), a new water-soluble NO generating polymer is obtained.  C-ebselen-
based LbL films are fabricated by alternatively assembling the resulting e-PEI and 
sodium alginate (Alg) onto a suitable substrate and further annealed to obtain a more 
robust and stable film with minimal Se leaching. The annealing mechanism is studied in 
detail.  Finally, the NO generation and antimicrobial properties of the final LbL films are 
also examined.   
3.2 Experimental 
3.2.1 Materials 
3,3'-diselenodipropionic acid (SeDPA) was synthesized using a reported method
1
.  
Ebselen, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), N-hydroxysuccinimide 
(NHS), 2-(N-morpholino)ethanesulfonic acid (MES), rhodamine B (RB), fluorescein-5-
thiosemicarbazide (FTSC), redistilled nitric acid (99.999% trace metals basis), 
polyethyleneimine (PEI, Mw 25 kD), sodium alginate (Alg, Mw 12-80 kD) and 
poly(dially dimethyl ammonium chloride) (PDDA, Mw 100-200 kD) were purchased 
from Sigma-Aldrich (St. Louis, MO).  NMR reagents were from Cambridge Isotope 
Laboratories, Inc. (Andover, MA). S-nitrosoglutathione (GSNO) and S-nitrosocysteine 
(CysNO) were freshly prepared as previously reported
1
.  Phosphate buffered saline 
(PBS), pH 7.4, containing 137 mM NaCl, 2.7 mM KCl, 10 mM sodium phosphate, was 
used in all experiments.  All solutions were prepared with deionized water from a Milli-Q 
system (18 MΩ cm
-1
; Millipore Corp., Billerica, MA).  Pseudomonas aeruginosa (P. 
aeruginosa) PAO300, a mucA22 derivative of PAO1 that constitutively overproduce 
alginate
2
 was obtained from the University of Copenhagen, Denmark.  Escherichia coli 
(E. coli) K-12 MG16653 and Staphylococcus aureus (S. aureus) ATCC 45330 were 
purchased from American Type Culture Collection.  Luria Bertani (LB) agar and broth 
were products of Fisher Scientific Inc. (Pittsburgh, PA).  
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3.2.2 Synthesis of C-ebselen and immobilization of C-ebselen on PEI 
C-ebselen was synthesized using a reported method
3
 with the minor modification of 
using anhydrous acetonitrile
4
 instead of ether as the solvent in the third step. 
1
H NMR, 
13
C NMR spectra and mass spectra of C-ebselen were recorded using a Varian MR400 
MHz, Varian VNMRS 700 MHz spectrometer and a VG (Micromass) 70-250-S Magnetic 
sector mass spectrometer (EI, 70eV), respectively.  
1
H NMR (400 MHz, DMSO-d6):  12.92 (s, 1H, -COOH), 8.11-8.09 (d, J=8.0 Hz, 1H, 
ArH), 8.02-7.99 (d, J=8.8 Hz, 2H, ArH), 7.93-7.91 (d, J=7.6 Hz, 1H, ArH), 7.86-7.84 (d, 
J=8.4 Hz, 2H, ArH), 7.72-7.69 (t, J=7.6, 1H, ArH), 7.51-7.48 (t, J=7.4 Hz, 1H, ArH). 
13
C 
NMR (176 MHz, DMSO-d6):  166.72, 165.33, 144.07, 138.65, 132.65, 130.48, 128.59, 
128.10, 127.17, 126.41, 125.87, 123.39.  The 
1
H NMR and 
13
C NMR spectra are shown 
in Figure 3.2. EI-MS m/z [M]
+
 calculated for C14H9NO3
80
Se, 319.0 (nominal mass), 
measured 319.1, measured isotope pattern matches predicted pattern for C14H9NO3Se. 
C-ebselen immobilized PEIs (e-PEI) with different Se contents were synthesized by 
EDC/NHS coupling of C-ebselen with PEI in pH 6.0 MES buffer.  Carboxyl:-NH2 molar 
ratios of 1:10 and 1:3 were selected for further studies.  C-ebselen was first dissolved in 
MES buffer and 2 M NaOH solution was added till a clear yellow solution was formed.   
EDC and NHS were then added to the solution (molar ratio -COOH: EDC: NHS=1:6:4) 
and the clear solution became turbid after 5 min.  A PEI solution in MES buffer was 
further added and the final pH was adjusted to 6.0 using 4 M HCl.  The reaction was kept 
at room temperature for 12 h.  The reaction mixture was then centrifuged and the 
polymers in the supernatant were further dialyzed (MWCO, 2 kD) against 0.05 M NaCl 
for 2 d and then Milli-Q water for 1 d.  The e-PEI obtained was then lyophilized and the 
Se content was determined by inductively coupled plasma - optical emission 
spectroscopy (ICP-OES) on a Perkin-Elmer Optima 2000 DV (Perkin-Elmer, Wellesley, 
MA) to be 1.87 wt% and 4.14 wt%, respectively, for the two different e-PEI preparations.  
 
54 
 
 
Figure 3.2. NMR spectra of carboxyl-ebselen in DMSO. 
 
3.2.3 Labeling e-PEI and Alg with fluorophores 
The e-PEI was labeled with RB and Alg was labeled with FTSC by the EDC/NHS 
reaction for 12 h in MES buffer, pH 6.0, using molar ratio EDC: fluorophore: NHS: -
NH2/–COOH = 1:1:1:20.  The labeled polymer was then washed and dialyzed extensively 
in the dark before use.  
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3.2.4 Layer-by-Layer assembly of e-PEI/Alg  
Glass and quartz slides were cleaned with piranha solution (7:3 H2SO4/30% H2O2) at 
80 ºC before use (Caution: the solution is extremely corrosive!) and the LbL films were 
prepared by alternately dipping the substrates in 1 mg mL
-1
 e-PEI and Alg solutions in 
pH 7.4 PBS (10 min each) with three intermediate PBS washings (1 min each) using a 
homemade automated deposition system until the desired number of bilayers were 
assembled onto the substrate.  The as prepared LbL films were further placed in a salt 
annealing solution (PBS buffer containing 1.5 M NaCl) for 1 min and then cross-linked 
for 12 h in a cross-linking solution (PBS buffer containing 1.5 M NaCl and EDC/NHS 50 
mM).   
3.2.5 Characterization of LbL films 
3.2.5.1 UV-Vis spectra 
The UV-Vis spectra of LbL films on quartz slides were recorded on a UV-Vis 
spectrophotometer (Lambda 35, Perkin-Elmer, MA).  The quartz slides were placed 
vertically into a quartz cuvette containing 3 mL buffer solution and the UV-Vis spectra 
were recorded with a resolution of 1 nm.  To record the spectra of the film after salt 
annealing, the film was placed in the salt annealing solution for 1 min and then 
transferred to another cuvette containing the annealing solution for recording the spectra.   
3.2.5.2 NO generation detection 
The catalytically generated NO from the LbL coatings was detected by purging N2 into 
2 mL pH 7.4 PBS solution in an NOA cell protected from light and monitored using a 
chemiluminescence NO analyzer (NOA) (Sievers 280, Boulder, CO).  For the 
homogeneous experiments with different organoselenium species, the Se-based catalysts 
were dissolved in DMSO while reducing agent and RSNOs were freshly prepared in pH 
7.4 PBS to form 5 mM solutions, respectively.  Lyophilized e-PEI was dissolved as a 1 
mg mL
-1
 solution in PBS.  Glass slides with LbL coatings were soaked in PBS containing 
100 μM EDTA, 100 μM GSH overnight before the NOA test.  To monitor the effect of 
superoxide (O2
•-
) scavenging, air instead of N2 was used for the purging.  
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3.2.5.3 Scanning electron microscopy 
Scanning electron microscopy (SEM) images were recorded on a Hitachi S-3200N 
scanning electron microscope (Hitachi High Technologies, Tokyo, Japan) at a working 
distance of 15 mm at 16 kV.  Glass slides with the LbL coatings were dip-washed with 
Milli-Q water, dried in a desiccator overnight and then sputter-coated with gold for 30 s 
before imaging.   
3.2.5.4 Optical microscopy and confocal laser scanning microscopy 
Glass slides with LbL coatings were placed in CoverWell perfusion chambers (Sigma-
Aldrich, St. Louis, MO) containing PBS buffer or the salt annealing solution for solution 
phase imaging.  Optical microscopy images were recording on a Nikon Eclipse E600 
POL optical microscope (Nikon Instruments, Inc., Melville, NY) using a 20 or a 40 
objective lens.  A Zeiss LSM 510-META confocal laser scanning microscope (Carl Zeiss 
Microimaging, Inc., Thoronwood, NY) was used for recording confocal images in PBS 
buffer or annealing solutions.  The fluorophores were excited by an Argon laser at 488 
nm and a HeNe laser at 543 nm and observed with a C-Apochromat 63 objective lens 
using two filters (505-550 nm, 560 nm).  The images were scanned at a speed of 1.6 s 
/ pixel using a 12 bit plane mode.  The image size was 10241024 pixels, which 
corresponds to an area of 143 m 143 m.  
3.2.5.5 Selenium content and Se leaching tests 
Fresh LbL films on glass slides were digested using fuming nitric acid and further 
diluted to a 10 mL final volume and the Se content of the films was determined via 
inductively coupled plasma - optical emission spectroscopy (ICP-OES) on a Perkin-
Elmer Optima 2000 DV (Perkin-Elmer, Wellesley, MA).  The Se leaching test was done 
by placing a (e-PEI/Alg)100 film in 9 mL of PBS buffer containing 100 M EDTA, 50 
M GSH and 50 M GSNO at 37.5 C in the dark for 24 h.  Each day, the soaking 
solution was collected, diluted to 10 mL and replaced.  After one week, the Se contents in 
the daily soaking solutions were measured with inductively coupled plasma high-
resolution mass spectrometry (ICP-HRMS), using a Thermo Finnigan Element (Thermo 
Electron Corp., Schaumberg, IL).  
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3.2.6 In vitro blood test  
Fresh heparinized (5 U mL
-1
) sheep or pig whole blood was obtained from 
Extracorporeal Membrane Oxygenation (ECMO) Laboratory in the Medical School at the 
University of Michigan.  The blood was centrifuged at 1300 rpm for 15 min to obtain 
platelet-rich sheep plasma (PRP).  Kendall monoject veterinary polyurethane (PU) I.V. 
catheters (Tyco Healthcare) were first modified by annealed (e-PEI/Alg)50 LbL films and 
then placed in PBS buffer, sheep plasma and whole sheep blood for 24 h at 4 C, 
respectively.  The catheters were dip washed by PBS before testing NO generation from 
RSNOs with the NOA.  The NO generation from a solution of pH 7.4 PBS containing 
100 M EDTA, 10 M CysNO and 20 M CySH at 37.5C was monitored.  Six glass 
slides with the same coatings were also used for the experiment (duplicate for each 
soaking experiment) and after the NOA test, the LbL film on glass slides was digested by 
fuming nitric acid and the Se content was determined by ICP-OES.  For long-term 
catalytic activity studies, the modified catheters were soaked in PBS buffer or pig blood 
for a week at 4 C and the RSNO decomposition catalytic activity was then evaluated. 
3.2.7 Detection of superoxide production by LbL films 
Superoxide (O2
•-
) produced from the LbL films constructed with e-PEI was detected 
using a previously reported lucigenin-derived chemiluminescence assay via a Shimadzu 
RF-1501 spectrofluorophotometer (Shimadzu, Columbia, MD).
5
  Forty L of 6.25 mM 
lucigenin (in DMSO) solution was mixed in 960 L of glycine-NaOH buffer (0.05 M, 
pH=10) in semimicro disposable cuvettes.  Annealed (e-PEI/Alg)50, annealed (PEI/Alg)50 
and (PDDA/Alg)50 films on glass slides were presoaked in 100 M EDTA and 100 M 
GSH PBS buffer overnight and then placed in the cuvettes to record the emission spectra.  
The chemiluminescence signal observed at 350-650 nm was integrated and the integrated 
intensity per unit area of the films was compared.  
3.2.8 In vitro antimicrobial tests  
Glass slides coated with LbL films were presoaked in PBS buffer containing 100 M 
EDTA and 100 M GSH before the antimicrobial tests in order to remove trace metal 
ions and reduce the catalytic sites into the selenolate form.  Overnight LB-broth grown 
bacterial culture was washed with PBS buffer three times, and resuspended in PBS buffer 
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to make a final cell concentration at 10
5
 or 10
8 
CFU/mL, respectively.  For solution phase 
antimicrobial tests, LbL films coated glass slides were placed into Corning 15-mL tubes 
with 2 mL of washed bacterial culture with or without addition of GSH solution.  The 
tubes were incubated at 37.5 C for 2 h or 24 h with horizontally shaking at 150 rpm.  
After incubation, coated slides were removed and the bacterial culture was serially 10-
fold diluted in PBS buffer and 50 µL of each dilution was plated onto LB (Luria Bertani) 
agar plate for viable bacterial counting.  Annealed (e-PEI/Alg)n, annealed (PEI/Alg)50 and 
glass controls in bacterial solution containing 0 or 20 M GSH were also used to study 
the effect of bilayer numbers, while annealed (e-PEI/Alg)50, annealed (PEI/Alg)50 and 
glass controls in bacterial solution containing 0, 20 or 50 M GSH were used to study the 
effect of different concentrations of reducing agent.  Annealed (e-PEI/Alg)50 and glass 
controls were also used to study the influence of specific strains of different bacteria 
(including E. coli, P. aeruginosa and S. aureus)  on the antimicrobial properties of the 
LbL films and the influence of RSNO addition. All the antimicrobial tests were 
conducted in duplicate. 
For microscopic observation, glass slides with the annealed LbL films were placed in 
semi-micro disposable cuvettes and 0.5 mL of washed bacterial culture was added to a 
final cell concentration of 10
5
 CFU/mL.  GSH was added to reach a final concentration of 
50 M.  The solution was incubated at 37.5 C for 2 h with horizontally shaking at 150 
rpm.  After incubation, the LbL coated slides were removed and stained with fluorescent 
dyes (SYTO-9 and propidium iodide) for 20 min in dark according to the instructions of 
the LIVE/DEAD® BacLight™ Bacterial Viability kit (L7012, Invitrogen, Carlsbad, CA).  
Stained slides were observed with a fluorescence microscope (Olympus 1X71, Center 
Valley, PA) equipped with Fluorescence Illumination System (X-Cite 120, EXFO) and 
appropriate filter sets.  Images were obtained using an oil immersion 60 × objective lens.  
Untreated glass slides were used as controls. Three images were taken for the same film 
and used for quantitative analysis. The images were analyzed using COMSTAT software 
(version 1)
6
 with the threshold setting as 25 and the surface bacterial coverage and deal 
cell percentage for glass slide, (PEI/Alg)50 and (e-PEI/Alg)50 were compared.  
3.2.9 In vitro antibiofilm test 
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A CDC biofilm reactor (Biosurface Technologies, Bozeman, MT) was used for the 
anti-biofilm test.  CDC biofilm reactor with its coupon holders was autoclaved before 
use.  Coated slides were mounted on coupon holders and the reactor was supplemented 
with 10% LB medium by a peristaltic pump with a continuous flow rate at 100 ml/h.  
Green Fluorescent Protein (GFP)-labeled E. coli culture was diluted 1:100 and inoculated 
into the glass vessel of CDC reactor aseptically.  The liquid growth medium was 
circulated through the vessel and shear force was generated by a magnetic stir bar rotated 
by a magnetic stir plate.  GSH was added to the circulating medium to reach a constant 
reducing agent concentration of 50 M.  Biofilms developed on the surface of coated 
slides were completely immersed into the circulated culture.  After 7 d incubation at 
room temperature (23 °C), coated slides were aseptically removed and individual slide 
surfaces were inspected under a fluorescence microscope (Olympus 1X71, Center Valley, 
PA) equipped with Fluorescence Illumination System (X-Cite 120, EXFO). Images were 
obtained using an oil immersion 60 × objective lens.   
3.3 Results and Discussion 
3.3.1 Identifying the key intermediate for C-ebselen catalytic activity 
Before working with LbL films, the homogeneous catalytic activity of C-ebselen for 
RSNO decomposition in solution phase was studied using GSH as the reducing agent in 
pH 7.4 PBS.  EDTA was added to eliminate the interference from free metal ion-induced 
RSNO decomposition.  As shown in Figure 3.3, this compound is able to generate NO 
from both GSNO (a) and CysNO (b).  It has been reported that selenol or selenolate is the 
key intermediate for the RSNO decomposition by organodiselenide species.
1
  For 
ebselen, the reaction with equal molar of GSH will first produce a GSH-selenenyl sulfide 
product, which will be further reduced to ebselen selenol in the presence of excess GSH 
(see reaction in Figure 3.4a).  The presence of an ebselen selenol intermediate has been 
verified elsewhere.
7
  The pKa for aliphatic selenols is ca 5.5,
1
 and an arylselenol should 
have an even lower pKa due to reduced electron density on the selenium atom.  
Therefore, at pH 7.4, in the presence of excess GSH, C-ebselen is in its selenolate form.  
In a homogeneous experiment in which different amounts of free C-ebselen catalyst were 
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added into a solution containing 100 M EDTA, 50 M GSNO and 50 M GSH, it was 
found that the NO generation was fastest when the molar ratio of GSH:C-ebselen = 2:1 
(Figure 3.4b).  When the molar ratio of GSH:C-ebselen was kept at 2:1, it was also 
found that the NO generation rate increased linearly with selenolate concentration 
(Figure 3.4c).  Therefore, C-ebselen selenolate is expected to be the key intermediate for 
the RSNO decomposition activity.   
 
 
Figure 3.3. Catalytic NO generation profiles indicating comparison of the RSNO 
decomposition catalytic activity of C-ebselen (A), SeDPA (B) and ebselen (C) in 
homogeneous solution with 100 M EDTA, 50 M selenolate and 50 M a) GSNO; b) 
CysNO; c) Structures of selenolate of SeDPA (A), C-ebselen (B) and ebselen (C). 
 
3.3.2 Comparison of RSNO decomposition activity of SeDPA, C-ebselen and ebselen  
The catalytic activities of SeDPA, C-ebselen and ebselen towards GSNO and CysNO 
decomposition were compared and are shown in Figure 3.3a and Figure 3.3b.  When the 
selenolate concentrations are kept the same for all three catalysts, SeDPA exhibits the 
best catalytic activity.  This is because aliphatic selenolates are better nucleophiles 
compared to aromatic ones due to the higher electron density on the Se atom.  The 
reduced steric hindrance owing to the smaller size of the SeDPA selenolate also 
contributes to the improved catalytic activity (see structures in Figure 3.3c).  C-ebselen, 
however, exhibits much better catalytic activity than ebselen.  It is possible that this 
improvement arises from the better solubility of C-ebselen-selenolate in an aqueous 
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phase coming from the ionization of the carboxyl group at neutral pH.  When CysNO, a 
smaller RSNO with less steric hindrance was used instead of GSNO, improved catalytic 
activity is observed for both C-ebselen and ebselen.   
 
 
Figure 3.4. a) Stepwise reaction between carboxyl-ebselen and GSH; b) Influence of C-
ebselen concentration on the NO generation in 100 M EDTA, 100 M GSH, 50 M 
GSNO, pH 7.4 PBS. NO generation was fastest when C-ebselen:GSH=1:2, indicating 
selenolate is the key intermediate; c) Influence of selenolate concentration on the NO 
generation in 100 M EDTA, 50 M GSNO, pH 7.4 PBS. C-ebselen:GSH=1:2. 
 
3.3.3 Catalytic activity of e-PEI  
Ebselen-PEIs with different C-ebselen to –NH2 molar ratios were synthesized and the 
Se content of the respective polymer was calculated from ICP-OES to be 1.87 wt% (e-
PEI-2) and 4.14 wt% (e-PEI-4), respectively.  Figure 3.5a inset shows the UV-Vis 
spectra of PEI (A), e-PEI-2 (B) and e-PEI-4 (C) at the same concentration (67 g mL
-1
) 
in pH 7.4 PBS buffer.  Due to the introduction of ebselen segments, the spectra of e-PEI 
solutions exhibit two bands.  While the absorption at 280 nm is from the benzene ring, 
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the absorption band at 350 nm is from the isoselenazol ring of the ebselen segments.
8
  
The ratio of C-ebselen moieties in the polymers calculated from the absorption 
differences at 280 nm was 2.2, which is consistent with the ICP results.   
 
 
 
Figure 3.5. a) Catalytic NO generation profiles indicating comparison of RSNO 
decomposition catalytic activity of C-ebselen (A), e-PEI-2(B) and e-PEI-4 (C) in solution 
with 100 M EDTA, 50 M selenolate and 50 M GSNO; inset shows the UV-Vis 
spectra of same concentration (67 g/mL) of PEI (A), e-PEI-2 (B) and e-PEI-4 (C) in 
PBS buffer; b) Schematic illustration of possibility of formation of hydrophobic centers 
in e-PEI-4 that prevent access of GSH and GSNO to the catalytic sites. 
 
The catalytic activities of e-PEI-2, e-PEI-4 and free C-ebselen were compared in pH 
7.4 PBS containing 100 M EDTA and 50 M GSNO.  The selenolate concentration was 
kept at 50 M for both polymers and C-ebselen.  As shown in Figure 3.5a, while e-PEI-2 
shows catalytic activity equivalent to free C-ebselen, e-PEI-4 with a higher Se content, 
exhibits reduced catalytic activity.  A proposed mechanism for the reduced catalytic 
activity is shown in Figure 3.5b.  It is possible that as the hydrophobic ebselen segments 
become denser (from higher C-ebselen loading on to polymer), the conformation of the 
amphiphilic e-PEI polymer will change in solution to form hydrophobic centers that 
prevent the access of GSH and GSNO to the catalytic sites.  In this case, not all the 
catalytic sites in e-PEI-4 can be fully used for catalytic RSNO decomposition, which may 
contribute to the reduced catalytic activity observed for this species.  Since e-PEI-2 has 
better catalytic activity, it was used to fabricate all the LbL films reported herein.  
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Figure 3.6. UV-Vis spectra of (e-PEI/Alg)50 on quartz slides. A) unannealed film in PBS; 
B) film after salt annealing in salt annealing solution. Inset shows the appearance of the 
films. 
 
3.3.4 Fabrication and annealing of LbL film 
The initially prepared LbL films exhibit a cloudy appearance (Figure 3.6, inset A) and 
are not stable.  As shown in Figure 3.7a-A, as soon as an unannealed (e-PEI/Alg)50 is 
placed in PBS buffer containing 100 M EDTA, 50 M GSH and 50 M GSNO, NO is 
generated due to the decomposition of the RSNO species by the catalytic sites in the LbL 
film.  However, the NO generation continues even after the film is removed, indicating 
significant leaching of catalytic sites from the film into the reaction reservoir.  The 
leaching is attributed to the heterogeneous nature of the unannealed film.  As shown in 
Figure 3.6A, the UV-Vis spectrum of an unannealed (e-PEI/Alg)50 exhibits large 
background signal from 400 nm to 700 nm, resulting from the light scattering of the 
heterogeneous film.
9
  The heterogeneous nature of the unannealed film is further revealed 
by SEM images shown in Figure 3.8A and Figure 3.8B.   The surface of the unannealed 
film is very rough, and it is composed of both vermiculate structures and particles.  Based 
on this surface morphology, it is highly unlikely that the film is in a thermodynamically 
stable state.  When this type of film is placed in solution for catalytic NO generation, 
chain rearrangements will likely take place to form a thermodynamically more stable 
structure, resulting in the leaching of the selenium species.   
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Figure 3.7. NO generation of a) (e-PEI/Alg)50 with no annealing (A), cross-link only (B) 
and two-step annealing (C) in 100 M EDTA, 50 M GSH, 50 M GSNO at R.T.; b) NO 
generation of LbL films with different bilayers on glass slides in 100 M EDTA, 50 M 
GSH, 50 M GSNO at R.T. (Inset: Se content of LbL films vs layer numbers.); c) NO 
generation of (e-PEI/Alg)100 in 100 M EDTA, 50 M GSH, 50 M GSNO at R.T.; d) 
NO generation from (e-PEI/Alg)50 on polyurethane catheters (inset) in 100 M EDTA, 20 
M CySH, 10 M CysNO at 37.5 C after 24 h soaking in PBS (A), sheep plasma (B) or 
sheep blood (C). The ↑or ↓arrow indicate the moment the film was placed in or taken out 
of the reaction reservoir. 
 
 
Layer-by-layer assembly, as indicated by Yang, et al., contains two steps: adsorption 
and chain rearrangement.
9
  While the former is a kinetically driven process that helps 
build the films, it also creates defects and results in thermodynamically unstable 
structures.  Chain rearrangement, on the other hand, helps in healing the defects, but is a 
slow and inefficient process.  To obtain a more robust and stable LbL film, it is necessary 
to heal the defects and change the heterogeneous nature of the initial film.  Therefore, the 
mobility of the polymer chains within the LbL film must be enhanced, and chain 
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rearrangements have to take place to form a more homogeneous structure, which needs to 
be further stabilized.  Based on this concept, a two-step annealing method was used to 
improve the stability of the LbL film and thereby to minimize the leaching of catalytic 
sites.  As shown in Figure 3.9, in the first step of annealing, salt is used to partly break 
the ionic bonds, enhance the chain mobility of the polyelectrolytes and turn a 
heterogeneous film into a homogeneous one.  In the second step, EDC/NHS is added to 
the annealing solution, so that the ionic bonds within the homogeneous film are turned 
into covalent linkages and the film is “locked” in its homogeneous state.   
 
 
Figure 3.8. Scanning electron microscopy (SEM) images of (e-PEI/Alg)50. A) B) without 
annealing; C) cross-link only; D) E) F) after two-step annealing.  
 
 
Salt-induced annealing is a convenient, universal and effective method to improve the 
homogeneity of LbL films.  When placed in the annealing solution, the unannealed (e-
PEI/Alg)50 turned from cloudy to clear within 1 min (Figure 3.6, inset B).  In addition, 
the background absorption in the UV spectra went back to zero (Figure 3.6B) after the 
salt annealing, indicating the formation of a homogeneous film.  However, if the salt 
concentration is less than 1.5 M, the film remains cloudy.  Since salt anneals the surface 
by temporarily breaking the electrostatic contacts and smoothing the surface, the change 
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will not happen immediately unless the salt concentration reaches a certain level of 
breaking enough contacts.
10
   
 
 
Figure 3.9. Schematic illustration of two-step annealing of LbL films including salt 
annealing and cross-linking. 
 
To monitor the surface morphology change in solution during the annealing process, e-
PEI and Alg were labeled with fluorophores and the surface morphology of the LbL films 
under different treatments were monitored using a confocal laser scanning microscope.  
As shown via the confocal images in Figure 3.10A, in PBS buffer, an unannealed (e-
PEI/Alg)50 shows a rough surface containing significant aggregates of micro-particle-
domains.  The morphology of e-PEI (red) and Alg (green) are the similar to each other, 
indicating the formation of polyion pairs throughout the film.  The surface morphology of 
the film in PBS buffer is different from the dry state SEM images shown in Figure 3.8A-
B, and this can be attributed to the polyelectrolyte conformation change from a stretched 
to a coiled conformation due to the reduced repulsion from the screening effect of salt.
11
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When the same film is placed in the salt annealing solution, the surface becomes smooth 
immediately as shown in Figure 3.10B.  With the breakage of the ionic bonds, the 
microparticle domains are dissociated, allowing new and lower energy configurations to 
form.  The salt annealing effect at solution phase is also observed by an optical 
microscope in Figure 3.11, and this is similar to a previously reported smoothing effect 
from salt annealing.
10
  
 
 
Figure 3.10. Confocal images of A) unannealed (e-PEI/Alg)50 in PBS; B) (e-PEI/Alg)50 
after salt annealing in PBS containing 1.5M NaCl; C) (e-PEI/Alg)50 after two-step 
annealing in PBS, e-PEI (red), Alg (green). 
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Figure 3.11. Optical microscope images of A) unannealed (e-PEI/Alg)50 in PBS; B) (e-
PEI/Alg)50 after salt annealing in annealing solution; C) (e-PEI/Alg)50 after two-step 
annealing in PBS. 
 
 
Although salt-annealing produced more homogeneous LbL films, the films were 
fragile and swelled considerably after extended exposure to the annealing solution.  
Therefore, it is necessary to cross-link the film immediately after brief exposure.  The 
cross-linking process is to “lock” the film in its homogeneous state by turning the ionic 
bonds into covalent linkages.  However, cross-linking alone does not produce a stable 
film.  As shown in Figure 3.7a-B, an (e-PEI/Alg)50 film treated only by cross-linking 
shows similar NO generation pattern to an unannealed film, indicating that cross-linking 
alone does not solve the leaching problem.  However, for a film treated with the two-step 
annealing process (Figure 3.7a-C), the NO detection signal goes back to nearly baseline 
once the film is removed from the reaction reservoir, indicating minimal leaching of Se 
species.  The NO flux of the annealed film, however, is lower than the unannealed one.  
This is consistent with a decrease in the Se contents for the LbL films after the annealing 
treatment (Figure 3.12a). Therefore, the reduced NO flux is attributed to reduction in the 
total amount of e-PEI adsorption resulting from the increased screening of surface 
charges in a highly concentrated salt solution.
12
  The surface morphology of the film with 
cross-linking only and the annealed films are compared in the SEM images shown in 
Figure 3.8.  As can be seen in Figure 3.8C, similar to the surface morphology of 
unannealed (e-PEI/Alg)50 in PBS buffer shown in Figure 3.10A, the surface of  (e-
PEI/Alg)50 treated by cross-linking only possesses significant micro-particle 
aggregations.  This is further proof that cross-linking alone can “lock” the film 
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morphology in solution phase by turning ionic bonds into covalent linkages.  Although 
the cross-linking restricts the chain mobility of LbL films, due to the rough surface and 
structural instability, the cross-linked film still suffers from significant leaching problem.  
The annealed film, on the other hand, shows a flat and smooth surface as shown in 
Figure 3.8D.  At higher magnification (Figure 3.8E), the entire film reveals a porous 3D 
structure, which is a thermodynamically stable network with minimal leaching.  The film 
thickness for (e-PEI/Alg)50 is 3.5 m (see Figure 3.8F).  The porous structure of the 
annealed film in PBS buffer is also observed by confocal microscope images shown in 
Figure 3.10C, indicating the consistency of the surface morphology of the film in a dry 
state and in contact with a solution phase.  The shift from a rough surface in PBS buffer 
to a smooth surface after the two-step annealing is also confirmed by optical microscope 
images shown in Figure 3.11. Compared to conventional LbL films, which are sensitive 
to environmental changes like pH and ionic strength, this type of film is a more stable 
and robust alternative.  
 
 
Figure 3.12. a) Comparison of Se content in LbL films before and after the annealing; b) 
Daily Se leaching from an annealed (e-PEI/Alg)100 in 100 M EDTA, 50 M GSH, 50 
M GSNO at 37.5 C for a week.  
 
3.3.5 NO generation and Se leaching from annealed LbL films 
The NO flux of the LbL films can be controlled by the number of bilayers that are 
incorporated into the films.  As shown in Figure 3.7b inset, the Se content of the LbL 
film grows exponentially with the number of bilayers within the films, which is 
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consistent with a previously reported growth for a PEI/Alg LbL film.
13
  In a PBS buffer 
containing 100 M EDTA, 50 M GSH, 50 M GSNO, the NO flux of the LbL film 
increases with increased number of bilayers, as shown in Figure 3.7b for (e-PEI/Alg)10 , 
(e-PEI/Alg)30 and (e-PEI/Alg)50.  However, when the catalyst content exceeds the 
substrate amount, the increase in the NO flux is less obvious as shown for (e-PEI/Alg)50 
and (e-PEI/Alg)100.  In these cases, it is likely that most of the RSNO substrate is 
consumed by the outer layers before it reaches the inner layers and reacts with the inner 
catalytic sites.  To investigate the stability of the LbL films, (e-PEI/Alg)100 with the 
highest Se content was repeatedly inserted and taken out of the reaction reservoir.  As 
shown in Figure 3.7c, no significant baseline signal increase is observed when the film is 
repeatedly taken out of the solution, indicating minimal leaching of Se species from the 
film.   
The leaching of Se species from a (e-PEI/Alg)100 film was monitored every day for a 
week using ICP-MS and the Se daily leaching was found to be 0.15~0.4 g cm
-2 
 (Figure 
3.12b).  Considering the small area of most medical devices (e.g. the surface of a catheter 
surface is normally less than 10 cm
2
), this value is far below the daily recommended 
intake of Se of 40 g d
-1
.
14
   
3.3.6 In vitro blood soaking experiment for annealed LbL films 
One of the advantages of LbL coatings lies in that they are applicable to a variety of 
substrates.  To determine whether the C-ebselen-based LbL films are potentially useful as 
coatings for blood contacting medical devices, the LbL films were assembled onto 
polyurethane (PU) catheters (shown in Figure 3.7d, inset) and the NO fluxes of the 
catheters after 24 h soaking in PBS buffer, sheep plasma and whole sheep blood were 
compared.  As shown in Figure 3.7d-A, in a reservoir of 20 M CySH and 10 M 
CysNO at 37.5 C, an (e-PEI/Alg)50 coating on a polyurethane catheter with PBS soaking 
exhibits an NO flux of 5.510
-10
 mol cm
-2
 min
-1
 and the NO flux is 310
-10
 mol cm
-2
 min
-
1 
for the film soaked in sheep plasma (Figure 3.7d-B) or whole blood (Figure 3.7d-C).   
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Figure 3.13. Comparison of Se content (black, left) and NO fluxes (light grey, right) of 
(e-PEI/Alg)50 on glass slides in 100 M EDTA, 20 M CySH, 10 M CysNO in pH 7.4 
PBS at 37.5 C after 24 h soaking in PBS, sheep plasma and sheep blood. 
 
 
To identify the reasons that contribute to the NO flux drop after blood or plasma 
soaking, the same experiments were conducted with (e-PEI/Alg)50 on glass slides and NO 
fluxes and the Se contents of films after different treatments were compared, as shown in 
Figure 3.13.  Although the films retain more than 80% of the total catalytic sites after 
plasma or blood soaking, the NO flux is only 55~ 60% of films that are only soaked in 
PBS buffer.  Therefore, the reduced NO flux is likely due to the combination of a loss of 
catalytic sites and protein adsorption on the LbL surfaces after plasma or blood soaking.  
In particular, protein adsorption might block the catalytic sites from interacting with 
thiols and RSNOs, and it might also scavenge NO generated from the films through 
nitrosation of any thiol groups.  When the catheter modified with (e-PEI/Alg)50 was 
soaked in pig blood for one week and placed into PBS buffer containing 20 M CySH 
and 10 M CysNO at 37.5 C, the NO flux hardly changed compared to the observation 
after 24 h (Figure 3.14).  Indeed, the LbL-film-based catheters are still able to generate 
physiological level of NO that are comparable with the healthy endothelial cell surface 
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(0.5~410
-10
 mol cm
-2
 min
-1
)
15
 even after one-week blood soaking, indicating their 
potential antithrombotic properties.   
 
 
 
 
Figure 3.14. NO generation from (e-PEI/Alg)50 on polyurethane catheters in 100 M 
EDTA, 20 M CySH, 10 M CysNO at 37.5 C after one week soaking in PBS buffer or 
pig blood. 
 
3.3.7 Antimicrobial properties of annealed LbL films 
The antimicrobial effect of aliphatic selenium species-based films have been reported 
and it is believed that superoxide (O2
•-
) produced from the reaction of aliphatic selenolate 
with oxygen is responsible for the observed antimicrobial activity.
14
   Due to reduced 
electron density on selenium atom, ebselen and its derivatives are reported to produce 
less superoxide (O2
•-
), which also contributes to their reduced in vivo toxicity.
16
  Since 
superoxide (O2
•-
) is a potent antimicrobial agent which causes oxidation stress and DNA 
damage to bacterial cells, even a small amount of superoxide (O2
•-
) production could lead 
to observable antimicrobial effects.  Therefore, the superoxide production from (e-
PEI/Alg)50 and (PEI/Alg)50 was assessed by a previously reported lucigenin-derived 
chemiluminescence assay.
5
  A (PEI/Alg)50 control produces 37% of the superoxide (O2
•-
) 
that is produced by (e-PEI/Alg)50 (Figure 3.15), indicating the introduction of only a 
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small percentage (1.87 wt% Se) of C-ebselen segments greatly increases the superoxide  
(O2
•-
) production of the polymer matrix.  The reason for the superoxide (O2
•-
) production 
from the (PEI/Alg)50 matrix without immobilized organoselenium sites is unknown.  
However, decreased superoxide (O2
•-
) production from the LbL film was observed by the 
EDTA pre-soaking procedure or replacing PEI with PDDA as shown in Figure 3.15, 
suggesting that trace metal ions that are strongly bound to PEI are responsible for the 
observed production of superoxide (O2
•-
) by the background LbL matrix components.  
 
 
Figure 3.15. Detection of superoxide (O2
•-
) produced from (PDDA/Alg)50, (PEI/Alg)50, 
(e-PEI/Alg)50 using a lucigenin-assay in pH=10 glycine-NaOH buffer. No signal was 
observed for a bare glass. 
 
The antimicrobial effects of ebselen and its derivatives have been reported,
17
 and the 
effect is suggested to be related to the S-N bond within this species.  Since ebselen tends 
to inhibit enzymes by interacting with their L-cysteine residues, the inhibition of enzymes 
such as H
+
-ATPase
18
 is reported to be one possible mechanism for the antimicrobial 
activity of ebselen and its derivatives.  
For LbL films with covalently attached ebselen segments, the antimicrobial effects are 
expected to be related to both superoxide production and the surface interactions of 
immobilized ebselen sites with bacterial cells.  In addition, since polyelectrolytes films 
have been reported to have antimicrobial functions by interacting with cell membranes,
19
 
the PEI/Alg backbone may also contribute to the antimicrobial effects observed with the 
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LbL films.  Among all the possible factors, only superoxide (O2
•-
) is likely to diffuse out 
of the LbL layer and kill the bacteria surrounding the LbL films in the bulk solution.  
Considering the small thicknesses of the LbL films (e.g., 3.5 m for (e-PEI/Alg)50  as 
indicated by SEM image Figure 3.8F) and the short lifetime of superoxide (O2
•-
), the 
killing effects are expected to take place in the localized vicinity of the film or in a 
contact-killing mode.  Therefore, both the antimicrobial properties of the LbL films in 
solution and the surface bacterial attachment were evaluated.   
 
 
Figure 3.16. Effects of e-PEI/Alg film layer number and reducing agent concentration on 
the cell viability of E coli. (e-PEI/Alg)10, (e-PEI/Alg)30, (e-PEI/Alg)50, (PEI/Alg)50 and 
glass slides control were placed in 10
5
 CFU/mL E. coli for 2 h at 37.5 C with and 
without GSH as the reducing agent. 
 
Solution-based antimicrobial tests were used to investigate the factors related to the 
bactericidal effects of the annealed LbL films.  (e-PEI/Alg)n, (PEI/Alg)50 and glass 
controls were placed in PBS buffer containing 10
5
 CFU/mL E. coli for 2 h at 37.5 C and 
aliquots of the solution were taken out after the time period to determine the viable 
bacterial counts in the solutions.  Given that the presence of a reducing agent is important 
for the production of the selenolate form of ebselen, which is required for generation of 
superoxide (O2
•-
), the influence of reducing agent concentration was also studied.  As 
shown in Figure 3.16, compared with the control glass slides, e-PEI/Alg films and 
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(PEI/Alg)50  exhibit different levels of antimicrobial effects.  Without the presence of a 
reducing agent, (e-PEI/Alg)10, (e-PEI/Alg)30 and (e-PEI/Alg)50 are able to kill 66.1%, 
95.6% and 98.2% of living E-coli cells in solution compared to a glass control that 
exhibits no killing effect. The killing efficacy increases with the number of bilayers that 
are incorporated into the e-PEI/Alg films, indicating a dose-dependent antimicrobial 
effect.  An increase in the bilayer number provides more catalytic sites to produce 
superoxide (O2
•-
), resulting in more bacteria killed in solution phase.  A (PEI/Alg)50 
control film is able to kill 72.2% of bacterial cells under the same condition, indicating 
the contribution from the polyelectrolytes backbone to the antimicrobial properties of the 
e-PEI/Alg films. However, considering the viable bacterial counts after the treatment 
with (e-PEI/Alg)50 film is only 6% of that for the (PEI/Alg)50, the increased superoxide 
(O2
•-
) production greatly improves the killing efficacy of the ebselen-based LbL films.  In 
the presence of 20 M GSH as the reducing agent, all the LbL films except the glass slide 
control exhibit better killing efficacy when compared to the case with no reducing agent 
added.  For (e-PEI/Alg)50 placed in bacteria solutions containing 0, 20 and 50 M GSH, it 
is clear that the killing efficacy increases with the reducing agent concentration in the 
solution.  While 2 logs of killing (i.e., the number of viable cells was reduced from 
~1.810
5
 to ~310
3
 CFU/mL) is observed for (e-PEI/Alg)50 film without reducing agent 
added, the killing effect is improved to 3 logs (i.e., the number of viable cells was 
reduced from ~2.410
5
 to ~810
2 
CFU/mL) with the addition of 50 M GSH. The 
reducing agent that facilitates selenolate formation will also facilitate superoxide (O2
•-
) 
production, thereby enhancing the antimicrobial properties of the coating.   
Considering most of the antimicrobial effects of the films take place near the surface, 
the surface bacterial attachment on (e-PEI/Alg)50, (PEI/Alg)50  and a glass slide control 
were compared after soaking in 10
5
 CFU/mL E. coli for 2 h at 37.5 C in the presence of 
50 M GSH.  As shown in Figure 3.17, although viable attached bacterial cells 
(indicated by green dots) are obvious on the surface of a bare glass (A) and (PEI/Alg)50 
(B), they are hardly observed on the (e-PEI/Alg)50 (C) surface. Quantitative analysis 
indicates that (e-PEI/Alg)50 and (PEI/Alg)50 are able to reduce 87% (~8 times reduction) 
and 56% (~2 times reduction) of total bacterial surface coverage compared to a glass 
slide (n=3, p<0.01, see Figure 3.18a).  For both (e-PEI/Alg)50 and (PEI/Alg)50 surfaces, 
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more than 92% (n=3, p<0.01, see Figure 3.18b) of total bacteria attached are dead or 
membrane damaged (indicated by red dots in Figure 3.17), demonstrating the killing 
effect at the surface. The difference between (e-PEI/Alg)50 and (PEI/Alg)50 for total 
bacterial attachment, especially living bacterial attachment, clearly indicates that the 
ebselen segments and superoxide (O2
•-
) production play important roles in improving the 
antimicrobial properties of the LbL films.  It is likely that superoxide (O2
•-
) present in the 
vicinity of the film kills the bacterial cells before they reach and attach onto the surface, 
and thus helps to repel living bacterial cells and reduce total bacterial surface coverage.  
 
 
Figure 3.17. Representative fluorescent micrographs showing comparison of surfaces of 
A) bare glass; B) (e-PEI/Alg)50; C) (PEI/Alg)50 after soaking in 10
5
 CFU/mL E coli 
containing 50 M GSH for 2 h at 37.5 C. Bacterial cells were stained with Bacterial 
LIVE/DEAD staining dyes and viable cells shown green while dead or membrane 
damaged cells shown red fluorescence in the images. 
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Figure 3.18. Quantitative analysis of a) bacterial surface coverage percentage; b) dead 
cell percentage of attached cells for glass slides, (PEI/Alg)50 and (e-PEI/Alg)50 surface 
after soaking in 10
5
 CFU/mL E. coli containing 50 M GSH for 2 h at 37.5 C. Bacterial 
cells were stained with Bacterial LIVE/DEAD staining dyes and images from the same 
films were processed with COMSTAT software (n=3, p<0.01).  
 
The antimicrobial effect of the LbL films was also found to be time and bacteria type 
dependent.  When (e-PEI/Alg)50 was placed in 10
5
 CFU/mL E. coli at 37. 5 C, it was 
found that all the bacteria were killed after 24 h (data not shown), indicating that a longer 
time exposure to superoxide (O2
•-
) helps to kill more bacteria in solution.  To determine 
whether the antimicrobial effect is universal, (e-PEI/Alg)50 was placed in 10
8
 CFU/mL of 
E. coli, P. aeruginosa and S. aureus for 24 h at 37.5 C.  As shown in Figure 3.19, the 
LbL films are able to kill a broad spectrum of bacteria with better killing efficacy 
observed for Gram positive S. aureus compared with Gram negative E. coli and P. 
aeruginosa, suggesting that the cell membrane structures of the given bacteria also 
influence the killing efficacy by the LbL films.  Considering that P. aeruginosa, S. aureus 
and E. coli are highly related to wound, catheter or urinary tract infections,
20, 21
 the C-
ebselen based LbL films have promising prospects in biomedical applications where such 
infections occur.  
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Figure 3.19. Antimicrobial properties of (e-PEI/Alg)50, in 10
8
 CFU/mL of E. coli, P. 
aeruginosa or S. aureus for 24 h at 37.5 C without and with 50 M GSH as the reducing 
agent.  Glass slides were used as controls. 
 
3.3.8 Antibiofilm properties of annealed LbL films 
To study the antibiofilm properties of the LbL coatings, a glass slide control and two 
glass slides with either the (PEI/Alg)50 or (e-PEI/Alg)50 coatings were incubated in a CDC 
biofilm reactor containing GFP-labeled E. coli at RT (23 C) for seven days.  For the 
films to continuously produce superoxide (O2
•-
), the GSH concentration in the circulating 
medium was kept at 50 M.  The antibiofilm properties of different surfaces are 
compared on the eighth day when the slides are removed from the reactor.  As shown in 
Figure 3.20, although a biofilm has colonized the control glass slide surface after the 
one-week incubation, both the (PEI/Alg)50 and (e-PEI/Alg)50 surfaces are clean, indicating 
significant antibiofilm properties.  Unfortunately, it is difficult to distinguish the 
differences between the antibiofilm properties of these two LbL coatings using the 
current method. 
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Figure 3.20. Fluorescent micrographs of E. Coli biofilm on the surface of A) glass slide; 
B) (PEI/Alg)50; C) (e-PEI/Alg)50 after 7 d antibiofilm test in a CDC biofim reactor, E. 
Coli was labeled by green fluorescence protein (GFP). 
 
 
3.3.9 Scavenging effect of NO and superoxide (O2
•-
) 
Although the NO and superoxide (O2
•- 
) generation from the carboxyl-ebselen-based 
LbL film suggests that this type of film has potential application as both an anti-thrombus 
and antimicrobial coating, to use this type of film as a coating with dual functionality, it 
is necessary to consider the scavenging effect coming from the reaction of NO and 
superoxide (O2
•- 
).  Recently, both modeling and experimental results suggest that the 
reaction between NO and superoxide (O2
•-
), which is faster than the reaction between NO 
and oxygen, contributes to the reduced detection limit observed for a selenocystamine-
based electrochemical RSNO sensor under ambient conditions compared to under 
nitrogen atmosphere.
5
  To evaluate the “NO scavenging effect” from superoxide (O2
•- 
) 
production, the NO generation behaviors of the C-ebselen and (e-PEI/Alg)50 in pH 7.4 
PBS containing 100 M EDTA, 20 M CySH and 10 M CysNO at 37.5C under N2 
atmosphere or air flow were compared and the results are shown in Figure 3.21a.  While 
in the presence of air, the superoxide (O2
•- 
) production scavenges ~30% of the total NO 
produced by the free C-ebselen, it also reduced the NO flux of (e-PEI/Alg)50 to ~74% of 
the flux under the N2 atmosphere.  The microbial killing effects, on the other hand, are 
similar when (e-PEI/Alg)50 films are placed in E. coli solution containing 100 M EDTA, 
20 M CySH with or without 10 M CysNO for 1 h (see Figure 3.21b) and this is 
attributed to the antimicrobial effect of both NO and peroxynitrite (ONOO
-
), the product 
of NO and superoxide (O2
•- 
) reaction.  Considering that significant levels of NO are still 
produced in the presence of ambient oxygen, it is likely that most of the anti-thrombotic 
80 
 
and antimicrobial properties of the LbL films will be retained even in the presence of this 
reaction.  When (e-PEI/Alg)50 films are placed in E. coli solution containing 100 M 
EDTA, 50 M CySH with or without 50 M CysNO for 1 h, however, a reduction in the 
antimicrobial property of the LbL films is observed when RSNO is added as shown in 
Figure 3.21b.  This is due to the excess of RSNO that competes with oxygen for the 
selenolates that are critical for superoxide (O2
•-
) production.  It also suggests that 
superoxide (O2
•-
) is a better antimicrobial agent compared with NO.  Therefore, most of 
the antimicrobial properties of the LbL films are attributed to the superoxide (O2
•-
) 
production from the immobilized ebselen segment.  However, since most of the 
antimicrobial property of the film is retained, the C-ebselen-based LbL films have 
potential to be used as dual functional coatings to prevent both thrombus formation and 
bacterial infection. 
 
 
Figure 3.21. a) NO generation in pH 7.4 PBS containing 100 M EDTA, 20 M CySH, 
10 M CysNO, 10 M C-ebselen at 37.5 C under N2 (A) or air (B) atmosphere.  The 
integration indicates superoxide (O2
•-
) production from ambient oxygen scavenges ~30% 
of total NO production.  Inset shows the NO generation from (e-PEI/Alg)50 in pH 7.4 
PBS containing 100 M EDTA, 20 M CySH, 10 M CysNO at 37.5
 
C under  N2 (A) 
or air (B) atmosphere; b) Antimicrobial properties of (e-PEI/Alg)50 in pH 7.4 PBS 
containing 10
5 
CFU/mL E. coli and different amounts of CySH and CysNO for 1 h at 
37.5 C. Glass slides were used as controls. 
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3.4 Conclusions 
Carboxyl-ebselen was used to generate NO from endogeneous RSNOs via a catalytic 
process. Further, a (e-PEI/Alg)50 coated polyurethane catheter, exhibiting minimal 
selenium leaching, was able to produce physiological levels of NO flux (~310
-10
 mol 
cm
-2
 min
-1
) from RSNOs after soaking in blood for one week.  The LbL film was also 
able to prevent living bacterial surface attachment, reduce biofilm formation and exhibit 
promising antimicrobial effects for a broad spectrum of bacteria through the production 
of superoxide  (O2
•-
) as the antimicrobial agent.  This type of film, exhibiting the potential 
for both antithrombotic and antimicrobial properties, may be useful to help resolve 
complications due to thrombus formation and bacterial infection associated with a wide 
range of biomedical devices such as catheters, vascular grafts and stents.  In addition, the 
simplicity of the LbL method also facilitates the automatic mass production of the 
coatings.  
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Chapter 4 Catalytic Activity of Cu(II)-Cyclen-Based Complexes and 
Copper Oxide Nanoparticles-Based Polymer Films Towards S-
Nitrosothiols 
 
 
4.1 Introduction 
   As described in Chapter 1, copper-based catalytic species including Cu(II)-complexes 
and Cu-based particles exhibit RSNO decomposition activity.  The ligand cyclen, for 
example, with a binding constant of 10
23
 M
-1
 to Cu(II) ion,
1
 has been covalently attached 
to different polymer backbones to fabricate NO generation polymers.
2-5
  Due to the strong 
binding with Cu(II) ion and open coordination sites of Cu(II)-cyclen that are still capable 
of interacting with reducing agents and RSNOs, Cu(II)-cyclen-based polymers are 
expected to have minimal leaching of copper ion and good catalytic activity towards 
RSNOs.  However, while the polymers exhibit good RSNO decomposition activity, their 
lifetimes are limited.  In fact, the NO generation mechanism for Cu(II)-cyclen-based 
polymers needs to be re-investigated due to the following factors: 1) The reported redox 
potential (-0.642 V vs. SCE) of Cu(II)-cyclen complex
6
 is very negative, so a strong 
reducing agent is needed for this Cu(II)-complex to be reduced into its Cu(I) form, which 
is the key intermediate for RSNO decomposition as described in detail in Chapter 1; and  
2) The RSNO decomposition catalytic activity of Cu(II)-cyclen has not yet been reported, 
so it is difficult to compare the catalytic activity of Cu(II)-cyclen and Cu(II)-cyclen-based 
polymers.   
In Chapter 1, the NO generation mechanism for copper-based particles was also 
described.  This process relies on the corrosion of the particles in solution to produce 
Cu
2+
 ions that are the catalytic species to decompose RSNOs.  Although Cu
0
  micro- or 
nanoparticles (NPs) have been utilized in NO generation coatings that have achieved in 
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vivo antithrombotic activity,
7, 8
 the corrosion rates of these types of particles are fast due 
to the redeposition/reformation of the inert surface oxides,
9
 which will further lead to 
toxicity issues and affect the lifetimes of copper particle-based NO generating coatings.  
In contrast to copper-based particles, which only have copper cores and thin layers of 
protective oxides, CuO NPs are homogeneously composed of inert copper (II) oxide and 
thus have slower corrosion rates.
9
  Therefore, CuO NPs are expected to be attractive 
alternatives to the previously used catalysts to further extend the lifetime for copper-
based NO generation materials. 
In this chapter, a mechanistic study is carried out to compare the coordination 
geometry, reduction potential and RSNO decomposition catalytic activity of Cu(II)-
cyclen, Cu(II)-cyclen derivative and Cu(II)-cyclen-tethered polymers.  The RSNO 
decomposition catalytic activity and copper leaching from Cu
0
 and CuO NPs-based 
polyurethane (PU) films is also studied and compared.  The long-term NO generation 
activity of the CuO NPs-based PU film is further studied, and it turns out that the film 
appears to be quite promising for potential biomedical applications.  
4.2 Experimental 
4.2.1 Materials 
1,4,7,10-Tetraazacyclododecane (cyclen) was purchased from Strem Chemicals Co 
(Newburyport, MA).  CuCl2•2H2O, anhydrous acetonitrile, glutathione (GSH), cysteine 
(CySH), CuO NPs (<50 nm, specific surface area (SSA): 29 m
2
/g), N,N'-
diisopropylcarbodiimide (DIC), N-hydroxysuccinimide (NHS), N-propylamine, 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and all the other chemical 
reagents were from Sigma-Aldrich (St. Louis, MO).  Ambersep®900, OH form ion 
exchange resin and all the other solvents were from Fisher Scientific (Fair Lawn, NJ). 
Cu
0
 NPs (40-60 nm, SSA: ~12 m
2
/g) were from SkySpring Nanomaterials, Inc. (Houston, 
TX).  Hydrophilic PU (HPU; Tecophilic, SP-93A-100, SP-60D-60, SP-60D-20) and 
Tecoflex PU SG-80 were gifts from Lubrizol Advanced Materials, Inc. (Cleveland, OH) 
and Cu (II)-cyclen PU (modified from SP-93A-100 PU) was synthesized by Sang-yeul 
Hwang, a previous group member, using a reported method.
3
  The copper content of 
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Cu(II)-cyclen PU was 0.4 wt%.  DI water was prepared by a Milli-Q filter system (18 
MΩ cm
-1
, Millipore Corp., Billerica, MA).  All the NMR reagents were from Cambridge 
Isotope Laboratories, Inc. (Andover, MA) and were used without further purification.  
4.2.2 Measurements 
1
H NMR spectra were recorded using a Varian 400 MHz spectrometer. Mass spectra 
were obtained using a Micromass LCT Time-of-Flight mass spectrometer.  EPR spectra 
were taken with a Bruker EMX (Center field, 3300 G, Sweep Width, 2000 G, Frequency, 
9.248 GHz).  UV-Vis spectra were recorded on a UV-Vis spectrophotometer (Lambda 
35, Perkin-Elmer, MA).  The XRD diffraction patterns were obtained on a Bruker D8 
Advance powder X-ray diffractometer with a 1.6 kW sealed tube X-ray source (Cu).  
Cyclic voltammograms (CVs) were recorded on a CHI electrochemical analyzer using a 
three-electrode system consisting of a glassy carbon electrode as the working electrode, a 
platinum counter electrode and a Ag/AgCl (3M KCl) as the reference electrode.  A scan 
rate of 100 mV s
-1
 was used for all the CVs.  A mixture of 67 mM Na2HPO4 and 0.1 M 
NaClO4 was chosen as the supporting electrolyte, as previously reported.
6
  The CuCl2 and 
ligand ratio was kept at 1:2 to minimize the concentration of free copper ion in solution.  
NO generated from various polymer films was detected by purging N2 into 2 mL pH 7.4 
PBS solution in an NOA cell protected from light and monitored using a 
chemiluminescence NO analyzer (NOA) (Sievers 280, Boulder, CO).  The leaching of 
copper from PU films containing different copper species was determined by inductively 
coupled plasma - optical emission spectroscopy (ICP-OES) on a Perkin-Elmer Optima 
2000 DV system (Perkin-Elmer, Wellesley, MA). 
4.2.3 Synthesis of amide derivative of cyclen 
N-propyl-2-cyclen-acetamide : 
(Boc)3-cyclen-N-acetic acid was synthesized according a previously reported method.
3
  
Five hundred mg (Boc)3-cyclen-N-acetic acid was dissolved in 50 mL anhydrous 
CH3CN, and then 217 mg NHS and 292 L DIC was added into the mixture and stirred 
until totally dissolved.  Ninety three L N-propylamine was then added to the mixture 
and the solution was bubbled with argon and stirred overnight. After the reaction, the 
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white precipitate was filtered and the residue was purified by a column chromatography 
using silica gel (EtOAC: Hexanes ratio gradually increased from 2:1, 3:1 to 4:1) to obtain 
(Boc)3-N-propyl-2-cyclen-acetamide species. 
1
H NMR (400 MHz, CDCl3): = 0.89 (t, 3H, CH3), 1.45 (27H, CH3 from Boc), 1.65 (2H, 
CH2 CH3), 2.59 (4H, CH2NCH2CO in cyclen), 3.14 (4H, CH2CO, CH2NH), 3.43 (12 H, 
CH2CH2NBoc in cyclen)  
MS: Calcd MW=571, found m/z: [M+Na] 
+
 594.3, [M+H] 
+
 572.3  
 
 
Scheme 4.1. The synthesis of N-propyl-2-cyclen-acetamide. 
 
To remove the Boc groups, 350 mg (Boc)3-cyclen-N-acetic acid was dissolved in a 
mixture of 2 mL CH2Cl2/TFA (trifluoroacetic acid) (1:19) and the reaction mixture was 
stirred for 4 h at RT.  The solvent was then removed by a rotovap and the residue was 
then extracted with Et2O/H2O (20 mL/20 mL). The water layer was then passed through 
an ion-exchange column containing 54.6 mL Ambersep®900 and the final solution was 
collected and lyophilized to obtain the final product.  
1
H NMR (400 MHz, D2O): =0.71 (t, 3H, CH3), 1.35 (m, 2H, CH2CH3), 2.54 (12 H, 
CH2CH2NH in cyclen), 2.64 (4H, CH2NCH2CO in cyclen), 3.04 (m, 4H, CH2CH2CH3, 
NCH2CO) 
MS: MW calcd 271, found m/z [M+H] 
+
 272.2 
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4.2.4 Pretreatment of CuO NPs 
Twenty mg of CuO NPs were dispersed in 1.5 mL of 100 M or 200 M EDTA to 
obtain a homogeneous dispersion and then centrifuged at 4000 rpm
 
for 5 min.  The 
supernatant was then removed and this washing process was then repeated once using 
100 M or 200 M EDTA and twice with distilled water.  
4.2.5 Fabrication of CuO or Cu NPs-based PU film 
Tecophilic or Tecoflex PUs were dissolved in THF to obtain a 20 mg mL
-1
 solution.  
CuO NPs were initially treated and washed using 100 M EDTA as described in Section 
4.2.4, and further dispersed into THF to obtain a 20 mg mL
-1
 dispersion.  One mL of the 
CuO NP dispersion was then mixed with 5 mL PU solution and 3 mL of the mixture was 
then added into a Teflon microplate well (d=2.6 cm and h=0.5 cm, 1.5 mL of the 
dispersion was added at a time) and left to dry overnight.  For comparison, Cu
0
 NPs with 
the same pre-treatment were used and a concentration of 16 mg mL
-1
 was utilized for the 
Cu NP THF solution to obtain the final Cu NPs-PU film with the same copper content as 
the CuO NPs-PU films.  Small pieces (d=9 mm) of the film were then used for further 
studies.  
4.2.6 Copper leaching detection from copper-based PU films 
To compare the influence of reducing agent on the leaching of copper from the Cu(II)-
cyclen PU, the Cu(II)-cyclen PU films were prepared by adding 0.5 mL of 20 mg mL
-1
 
Cu(II)-cyclen PU per well into teflon microplate wells (d=1 cm).  The films were then 
placed in 2 mL PBS buffer or PBS buffer with 20 mM GSH at 37 C and the soaking 
solutions were collected and replaced on the second, third, fifth and seventh days.  GSH 
solution was freshly prepared each time during the replacement of the soaking solution.  
The collected soaking solutions were then combined and the accumulated copper 
leaching amounts over the six day period were then detected by ICP-OES.  The leaching 
experiments were done in triplicate using three Cu(II)-cyclen PU films. 
To compare the leaching of copper from Cu or CuO NP-based PU (SP-60D-60) films, 
the films (d=9 mm) were soaked in 5 mL PBS buffer containing 50 M EDTA, 50 M 
GSH and 50 M GSNO at 37 C.  The soaking solutions were collected and replaced on 
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the second, third fifth and seventh day.  The GSH/GSNO solution was freshly prepared 
each time during the replacement of the soaking solution.  Two mL nitric acid was added 
into each collected soaking solution and the copper leaching amounts were then detected 
by ICP-OES.  All the leaching experiments were done in triplicate utilizing three Cu or 
CuO NP-based PU films. 
4.2.7 Long-term NO generation catalytic activity of CuO NPs-PU film 
To evaluate the potential long-term NO generation catalytic activity of CuO NPs-PU 
films, a CuO NPs doped SP-60D-60 film was placed in solution containing 50 M 
EDTA, 50 M GSH and 50 M GSNO at 37 C and the NO that is generated from the 
film was then detected by the NO analyzer.  The film was then removed from the reaction 
reservoir and was inserted and taken out repeatedly to evaluate the stability of the 
catalytic sites within the film.  While not in use, the film was stored in PBS buffer 
containing 50 M EDTA, 50 M GSH and 50 M GSNO at 37 C.  The NO flux was 
monitored periodically over sixteen days in freshly prepared test solution with the same 
compositions.  The soaking solution was replaced after each evaluation of the film’s 
catalytic activity.   
4.3 Results and Discussion 
4.3.1 RSNO decomposition catalytic activity of Cu (II)-cyclen complexes and Cu(II)-
cyclen PU film 
  Initially, the catalytic activity of a previously developed Cu(II)-cyclen PU film was 
studied and as shown in Figure 4.1A, the film exhibits good catalytic activity for 
converting GSNO into NO when GSH is used as the reducing agent and this is consistent 
with previously reported results.
3
  However, when Cu(II)-cyclen (not linked to polymer) 
is utilized under the same conditions, hardly any NO is generated (data not shown).  
Therefore, different reducing agents and RSNOs were further employed to reinvestigate 
the RSNO decomposition catalytic activity of Cu(II)-cyclen and the results are shown in 
Figure 4.2.  In all the studies, EDTA and an excess of cyclen were added to minimize the 
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presence of free copper ion in solution.  As shown in Figure 4.2a-B, the Cu(II)-complex 
exhibits catalytic activity towards GSNO in the presence of CySH, a stronger reducing 
agent compared with GSH.
3
  This is consistent with the hypothesis that a strong reducing 
agent is needed to convert the Cu(II)-complex into its Cu(I) form due to the negative 
redox potential of Cu(II)-cyclen.
6
  When CySNO, a RSNO with reduced steric hindrance 
is used instead of GSNO, better RSNO decomposition catalytic activity is observed for 
the Cu(II)-cyclen (see Figure 4.2a-A and Figure 4.2b-A).  The catalytic activity towards 
CySNO is decreased when GSH, a weaker reducing agent is employed, as shown in 
Figure 4.2b-B. 
 
 
 
 
Figure 4.1. A) NO generation from a Cu(II)-cyclen PU film (d=1.4 cm, prepared from 1 
mL 4 wt% Cu(II)-cyclen-PU) in pH 7.4 PBS buffer containing 20 μM EDTA, 50 μM 
GSH, 50 μM GSNO; B) structure of Cu(II)-cyclen PU. 
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Figure 4.2. a) Catalytic NO generation from HEPES buffer (pH=7.04) containing 20 μM 
EDTA, 50 μM CySH, 50 μM Cu(II)-Cyclen (1:1.5) with 50 μM CySNO (A) or 50 μM 
GSNO (B); b) Catalytic NO generation from HEPES buffer (pH=7.04) containing 20 μM 
EDTA, 50 μM CySNO, 50 μM Cu(II)-Cyclen (1:1.5)  with 50 μM CySH (A) or  50 M 
GSH (B). 
 
4.3.2 Comparing the reduction potential, coordination geometry and catalytic 
activity between  Cu (II)-cyclen and Cu(II)-cyclen amide complexes 
The above studies suggest that Cu(II)-cyclen PU has better catalytic activity when 
compared to the Cu(II)-cyclen complex.  Since an amide bond is formed between the 
cyclen derivative and polyurethane backbone during the Cu(II)-cyclen PU synthesis, the 
amide bond might contribute to the improved catalytic activity of Cu(II)-cyclen PU.  
Therefore, N-propyl-2-cyclen-acetamide, an amide derivative of cyclen was synthesized 
to investigate the influence of the addition of amide bond on the catalytic activity of the 
Cu(II)-cyclen complex.  
Firstly, to investigate whether the amide bond will shift the reduction potential of 
Cu(II)-cyclen, the cyclic voltammograms (CVs) of free copper salt, Cu(II)-cyclen and 
Cu(II)-cyclen amide derivative on a glassy carbon electrode were examined and are 
shown in Figure 4.3.  The CV for free CuCl2 on the glassy carbon electrode under a N2 
atmosphere at a scan rate of 100 mV s
-1
 is shown in Figure 4.3a-A and two pairs of 
peaks are observed corresponding to Cu(II)/Cu(I) and Cu(I)/Cu(0) redox couples as 
previously reported.
10
  The cathodic peak corresponding to Cu(II)/Cu(I) reduction (c1) is 
located at -0.0475 V (vs. Ag/AgCl).  In the presence of air, however, the cathodic peak 
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corresponding to Cu(I)/Cu(0) (c2) disappears as shown in Figure 4.3a-B, which is 
probably due to the instability of Cu(I) under ambient conditions.  Therefore, all the CVs 
for Cu(II)-complexes were recorded under a N2 atmosphere.  
 
 
Figure 4.3. a) Cyclic voltammograms (CVs) of 1 mM CuCl2 in solution containing 0.1 M 
NaClO4, 67 mM Na2HPO4 under N2 (A) or air (B) atmosphere at 100 mV/s on glassy 
carbon electrode; b) CVs of 2 mM cyclen (A) or 1 mM Cu-cyclen (CuCl2: cyclen=1:2) 
(B) on glassy carbon electrode at 100 mV/s under N2. Supporting electrolytes 0.1 M 
NaClO4, 67 mM Na2HPO4; c) CVs of 2 mM cyclen amide (A) or 1 mM Cu-cyclen amide 
(CuCl2:cyclen amide=1:2) (B) on glassy carbon electrode at 100 mV/s under N2. 
Supporting electrolytes 0.1 M NaClO4, 67 mM Na2HPO4. 
 
 
The CVs of cyclen and Cu(II)-cyclen on the glassy carbon electrode under a N2 
atmosphere at a scan rate of 100 mV s
-1
 are compared and shown in Figure 4.3b-A and 
Figure 4.3b-B, respectively.  The cathodic peak corresponding to Cu(II)-cyclen/Cu(I)-
cyclen reduction (c1) is located at -0.902 V (vs. Ag/AgCl), indicating Cu(II)-cyclen is 
very difficult to be reduced compared to free copper ion, which is consistent with 
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previous observations.
6
  The cathodic peak corresponding to Cu(II)-cyclen amide/Cu(I)-
cyclen amide reduction (c1), on the other hand, is located at -0.800 V (vs. Ag/AgCl) (see 
Figure 4.3c-B).  The 100 mV positive shift might result from the electron withdrawing 
effect of the amide bond which weakens the binding of cyclen with Cu(II) and facilitates 
the reduction of the Cu(II) complex into its Cu(I) form.   
 
 
 
Figure 4.4. a) EPR spectra of Cu(II)-cyclen and Cu(II)-cyclen-amide in solution 
containing 0.1 M NaClO4 and 67 mM Na2HPO4 at 77K: Center field, 3300 G; Sweep 
width, 2000 G; Frequency, 9.248 GHz;  b) UV-Vis spectra of 1 mM Cu(II)-cyclen (1:2) 
in 0.1 M NaClO4, 67 mM Na2HPO4 (A), Cu(II)-cyclen-amide (1:2) in 0.1 M NaClO4, 67 
mM Na2HPO4 (B) and 1 mM CuCl2 in 0.1 M NaClO4 (C). 
 
To evaluate whether the introduction of the amide bond causes any changes in the 
coordination geometry of Cu(II)-cyclen, the EPR spectra and UV-Vis spectra of Cu(II)-
cyclen and Cu(II)-cyclen amide are compared in Figure 4.4a and Figure 4.4b.  The same 
supporting electrolytes used in the CV studies were added to the solutions used for EPR 
and UV-Vis spectra to ensure the consistency of all the comparisons.  As shown in 
Figure 4.4a, the EPR spectra of both Cu(II)-cyclen and Cu(II)-cyclen amide exhibit the 
typical four-line patterns as previously reported for Cu(II)-cyclen and Cu(II)-cyclen 
polyurethane,
3
 indicating the addition of the amide bond does not cause any changes in 
the coordination geometry for the Cu(II)-cyclen complex.  For both Cu(II)-cyclen and 
Cu(II)-cyclen amide, the g values are 1.99, 2.03 and 2.13 for gx, gy and gz, respectively, 
indicating a square pyramidal symmetry with the ground state of dx
2
-y
2
.
11
  The UV-Vis 
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spectra of Cu(II)-cyclen and Cu(II)-cyclen amide exhibit maximum absorption at 
621max   nm and 586max   nm which are consistent with previously reported five-
coordinate geometry for the copper ion center.
11
  Therefore, both Cu(II)-cyclen and 
Cu(II)-cyclen amide derivative have five-coordinated square pyramidal structures and a 
water molecule or a solution ion such as Cl
-  
might act as the fifth ligand. 
 
 
Figure 4.5. a) Catalytic NO generation profiles from solution of 20 μM EDTA, 50 μM 
CySH, 50 μM CySNO with 50 μM Cu(II)-Cyclen (1:1.5) (A) and 50 μM Cu(II)-cyclen-
amide (1:10) (B) in HEPES buffer pH=7.4; b) NOA from solution of 20 μM EDTA, 50 
μM CySH, 50 μM GSNO with 50 μM Cu(II)-Cyclen (1:1.5) (A) and 50 μM Cu(II)-
cyclen-amide (1:10) (B) in HEPES buffer pH=7.04   
 
The RSNO decomposition catalytic activity of Cu(II)-cyclen amide was also studied 
and compared with Cu(II)-cyclen.  Initially, when GSH is used as the reducing agent, 
similar to Cu(II)-cyclen, no catalytic activity is observed for Cu(II)-cyclen amide towards 
GSNO.  The RSNO decomposition catalytic activity is observed only when CySH is used 
as the reducing agent and the comparison towards CySNO and GSNO are shown in 
Figure 4.5a and Figure 4.5b, respectively. Although the 100 mV positive shift of the 
reduction potential of Cu(II)-cyclen amide contributes to the improved catalytic activity 
of this complex towards CySNO, the improvement is not very significant as shown in 
Figure 4.5a.  When GSNO is used as the RSNO substrate, due to the steric hindrance, 
Cu(II)-cyclen exhibits even better catalytic activity compared to the amide derivative.  
Therefore, the introduction of an amide bond hardly improves the RSNO decomposition 
catalytic activity for the Cu(II)-cyclen complex. 
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4.3.3 Proposed mechanism for improved RSNO decomposition catalytic activity for 
Cu(II)-cyclen-based polyurethanes 
 
Figure 4.6. Six day accumulated copper leaching for Cu(II)-cyclen-PU film in PBS 
buffer without or with 20 mM GSH (n=3), the copper content of each film used is 40 g. 
 
The above comparison studies between the Cu(II)-cyclen and Cu(II)-cyclen amide 
complexes rule out the possibility that the introduction of the amide bond is contributing 
to the improved RSNO decomposition catalytic activity of Cu(II)-cyclen PU films.  Since 
it is reported that the cyclen structure is not able to trap coordinated Cu
+
 due to its 
increased ionic size (from 72 pm to 96 pm) and electron repulsion (from d
9
 to d
10
),
12, 13
 
when the Cu(II)-cyclen PU is in contact with a reducing agent, it is very likely that Cu
+
 
will leach out of the cyclen ring.  To prove that the cyclen ring is unable to stabilize Cu
+
, 
the accumulated copper leaching amounts of Cu(II)-cyclen-PU films soaked in PBS 
buffer with or without reducing agent were compared and the results are shown in Figure 
4.6.  In the presence of 20 mM GSH as the reducing agent, the accumulated copper 
leaching amount increases from 3.8% to 15.8%, which is ~4 times higher than the copper 
leaching amount in the absence of a reducing agent.  This result supports the hypothesis 
that the cyclen ring and the PU matrix are unable to fully stabilize Cu
+
.  When the Cu
+
 
leaches out from the cyclen ring, it may loosely bind to the urethane groups within the 
polymer matrix and eventually leach out.  The loosely bound Cu
+ 
is then likely 
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responsible for the improved RSNO decomposition catalytic activity and short lifetime of 
the NO generation polymer.   
 
4.3.4 RSNO decomposition catalytic activity of CuO NPs 
 
Figure 4.7. Catalytic NO generation profiles of 50 M CuO NPs A) without EDTA pre-
wash treatment; B)  with 100 M EDTA pre-wash treatment; C) with 200 M EDTA 
pre-wash treatment in PBS buffer containing 20 M EDTA, 50 M GSH and 50 M 
GSNO at 37C.  CuO NPs were prepared in PBS buffer as a 5 mM dispersion and 
aliquots were added into the reaction reservoir to reach a concentration of 50 M. 
 
 
To improve the lifetime of copper-based NO generation materials, CuO NPs, with a 
larger reservoir of copper compared to Cu(II)-cyclen complexes and slower corrosion 
rate compared to Cu NPs, were investigated as a novel catalyst for RSNO decomposition.  
The catalytic activities of CuO NPs with different treatments were first studied in PBS 
buffer containing 20 M EDTA, 50 M GSH and 50 M GSNO at 37 C.  As shown in 
Figure 4.7, the CuO NPs exhibit good catalytic activity towards GSNO when GSH is 
used as the reducing agent.  Improved catalytic activity for CuO NPs is observed when 
the particles are prewashed by EDTA solutions, and the higher the EDTA concentration 
in the washing solution, the better the catalytic activity of the particles after such 
treatment.  This improvement might come from the dissolution of the outer layers of the 
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NPs, which further facilitates the corrosion of the particles in solution.  However, an 
excess of EDTA will totally dissolve the CuO NPs.  Since both RSNO decomposition 
catalytic activity and lifetime are important for NO generation materials, 100 M was 
chosen as the EDTA wash concentration to improve the catalytic activity and retain most 
of the copper reservoir. 
 
4.3.5 RSNO decomposition catalytic activity of CuO NPs doped PU films 
To evaluate whether the CuO NPs can be incorporated into a polymer film for NO 
generation, the particles were dispersed into a SP-60D-60 PU matrix and the RSNO 
decomposition catalytic activity of CuO NPs-based PU film was studied and compared 
with a film containing Cu NPs with the same pre-treatment.  As shown in Figure 4.8A, 
when a Cu NPs-SP-60D-60 film is placed into a solution containing 100 M EDTA, 50 
M GSH and 50 M GSNO at 37 C, all the GSNO is decomposed within 10 min with a 
burst of NO generation, indicating a fast corrosion rate and high catalytic activity of Cu 
NPs-SP-60D-60 films.  Since both the burst of NO and fast corrosion of Cu NPs will lead 
to toxicity issues, alternative catalysts need to be developed.   
When a CuO NPs-SP-60D-60 film is inserted into PBS solution containing 50 μM 
EDTA, 50 μM GSNO, 50 μM GSH at 37 ºC, due to the much slower corrosion of the 
more inert CuO surface, a steady NO flux is observed as shown in Figure 4.8B and C.  
When the film is removed from the reaction reservoir, the NO generation immediately 
ceases, indicating minimized leaching of catalytic species from the film.  Without the 
EDTA washing pretreatment, the NO flux of the CuO NPs-PU film is ~57% (Figure 
4.8B) of the film containing particles with the pretreatment (Figure 4.8C), which is 
consistent with the previous observations of the influence of EDTA on the catalytic 
activity of CuO NPs.  The effect of the water uptake of the polyurethane matrices was 
also evaluated.  The water uptake values of SP-60D-60, SP-60D-20 and SG-80A are 60 
wt%, 20 wt% and <1 wt%, respectively.
14
  As shown in Figure 4.8C, D and E, the NO 
flux of the films decrease with a decrease of the water uptake of the polymer matrices.  
For SG-80A with barely any water uptake, the RSNO decomposition catalytic activity is 
poor because only the CuO NPs on the surface are accessible for the RSNO in the 
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substrate.  The higher the water uptake of the polymer, the more catalytic sites within the 
film will be accessible to low molecular weight GSH and GSNO, and, therefore, the 
better the catalytic activity of the CuO NPs-PU film.  To evaluate whether the CuO NPs-
PU film is capable of generating physiological levels of NO flux, a CuO NPs-SP-60D-60 
film was placed in a reservoir containing 50 M EDTA, 20 M GSH and 1 M GSNO 
and the result is shown in Figure 4.8F.  An NO flux of ~1.710
-10
 mol cm
-2
 min
-1
 is 
observed, which is comparable to that produced by the healthy endothelial cell surfaces,
15
 
indicating the potential antithrombotic activity of the CuO NPs-PU film.  
 
 
Figure 4.8. Catalytic activity of A) Cu NPs-SP-60D-60 film in 2 mL PBS (10 mM, 
pH=7.04) buffer containing 100 μM EDTA, 50 μM GSNO, 50 μM GSH at 37 ºC; B) 
CuO NPs-SP-60D-60 film (CuO NPs without EDTA pre-wash treatment); C) CuO NPs-
SP-60D-60 film; D) CuO NPs-SP-60D-20 film; E) CuO NPs-SG-80 film in 2mL PBS (10 
mM, pH=7.04) buffer containing 100 μM EDTA, 50 μM GSNO, 50 μM GSH at 37 ºC ; 
F) CuO NPs-SP-60D-60 film in 2 mL PBS (10 mM, pH=7.04) buffer containing 50 μM 
EDTA, 1 μM GSNO, 20 μM GSH at 37 ºC. Films were repeatedly inserting and taken out 
of the solution as indicated by the ↑and ↓arrows.  
 
4.3.6 Long-term catalytic activity from CuO NPs doped PU film 
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The long-term catalytic activity of the CuO NPs-SP-60D-60 film was further evaluated 
in solution containing 50 μM EDTA, 50 μM GSNO, 50 μM GSH at 37 ºC.  As shown in 
Figure 4.9, the film exhibits a gradually decreased NO flux over time for sixteen days 
with the depletion of the copper reservoir.  The decreased NO flux of the film on the first 
day (Figure 4.9A) compared to the previous result (Figure 4.8C) is due to the loss of 
catalytic sites during storage in the soaking solution and the NOA test.  Due to the ease of 
the fabrication of the CuO NPs-PU film, the lifetime of the coating is expected to be 
further controlled by controlling the CuO NPs composition and film thickness. 
 
 
Figure 4.9. Catalytic activity of CuO NPs-SP-60D-60 film in 2 mL PBS (10 mM, 
PH=7.04) buffer containing 50 μM EDTA, 50 μM GSNO, 50 μM GSH at 37 ºC on the A) 
first; B) third; C) fifth; D) eighth; E) twelfth; F) sixteenth day. The film was repeatedly 
inserting and taken out of the solution as indicated by the ↑and ↓arrows.  The film was 
stored in 10 mL PBS buffer containing 50 μM EDTA, 50 μM GSNO, 50 μM GSH at 37 
ºC and the storage solution was freshly prepared and replaced after each NOA test. 
 
4.3.7 Copper leaching from the Cu or CuO NPs doped PU film  
The leaching of copper from SP-60D-60 PU films containing CuO or Cu NPs was 
monitored over a six day period using ICP-OES and the copper daily leaching values of 
the two types of films are shown in Figure 4.10.  Considering the average daily uptake of 
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Cu by humans is 0.6~1.6 mg/day
7
 and the small area of most medical devices, none of 
the films are considered to leach toxic levels of copper.  However, the CuO NPs doped 
PU film, with a slower corrosion rate, obviously exhibits less leaching of copper 
compared with films containing Cu NPs loaded with the same copper weight percentage 
(calculated to be 13.8 wt%).  In addition, considering that the specific surface area of 
CuO NPs (29 m
2
/g) is higher than the Cu NPs (12 m
2
/g), their smaller sizes (active 
surface area per mass) can lead to more corrosion.  Therefore, when CuO NPs with the 
same size as the Cu NPs are utilized, less leaching should be observed than shown in 
Figure 4.10.  In addition, this result is consistent with a previously observed trend that 
CuO NPs with a larger surface compared with Cu NPs exhibit less leaching of copper in 
PBS buffer.
9
 
 
 
Figure 4.10. Copper leaching from CuO NPs or Cu NPs-doped SP-60D-60 film (D=9 
mm) on the first, second, fourth and sixth day (n=3).   
 
4.3.8 XRD patterns of CuO and Cu NPs 
To better understand the particle compositions utilized in these experiments, the XRD 
patterns of the CuO and Cu NPs employed herein are compared in Figure 4.11.  The 
XRD pattern of CuO NPs shown in Figure 4.11A can be indexed to monoclinic tenorite 
CuO, as previously reported.
16
  The XRD pattern of Cu NPs, in contrast, is complicated 
due to the presence of a surface oxide layer.
9
  As shown in Figure 4.11B, while most of 
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the peaks in the XRD pattern match the reported data for cubic copper, peaks for cubic 
Cu2O are also observable as reported previously for Cu NPs.
17
  A magnification of the 
oxide region is shown in the Figure 4.11B inset, which indicates the presence of both 
Cu2O and CuO on the surface of the copper NPs, as has been reported elsewhere.
9
  
According to the intensity of the strongest peak for each species, the relative proportions 
of Cu2O, CuO and Cu core are 3.9%, 1.9% and 94.2%, respectively.  The presence of 
Cu2O on the surface and the limited coverage of oxide layer on the surface of the Cu NPs 
contribute to the burst of NO generation from the reaction reservoir and faster corrosion 
rate of the copper NPs.   
 
 
Figure 4.11. XRD patterns of A) CuO NPs and B) Cu NPs. The inset shows the 
magnification and peak deconvolution of the oxide region which contains two peaks from 
CuO and one peak from Cu2O. The presence of surface Cu2O and CuO due to slow 
oxidation causes the peak broadening. 
 
4.4 Conclusions 
A mechanistic study suggests the better RSNO decomposition catalytic activity and the 
short lifetime of the Cu(II)-cyclen PU polymer material results from the inability of the 
cyclen cavity to hold Cu
+
.  In contrast, a CuO NPs-based PU film is capable of generating 
physiological levels of NO and its catalytic activity lasts for sixteen days due to the slow 
corrosion and release of Cu
2+
 from the film.  This type of film, with minimal copper 
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leaching and long-term catalytic activity, is expected to be an alternative to the previously 
developed Cu(II)-cyclen-based NO generation coatings. 
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Chapter 5 Conclusions and Future Directions 
 
5.1 Conclusions 
The research in this dissertation focused on developing antithrombotic and 
antimicrobial coatings based on two strategies: nitric oxide (NO) release and NO 
generation.  While previously developed NO release materials have been widely utilized 
for antithrombotic applications,
1-3
 in this dissertation, a focus was on investigating the 
antibiofilm properties of NO release coatings.  In Chapter 2, it was demonstrated that 
diazeniumdiolate (NONOate)-doped poly(lactic-co-glycolic) acid (PLGA)-based NO 
release films with controllable NO release patterns are capable of preventing biofilm 
formation under various conditions in a CDC biofilm reactor.  Specifically, an NO 
releasing film with a base layer of 30 wt% dibutyhexyldiamine diazeniumdiolate 
(DBHD/N2O2) mixed with poly(lactic acid) (PLL), is capable of NO release for 10 d at 
37 C and exhibited ~ 98.4% reduction in biofilm biomass of S. aureus and ~ 99.9% 
reduction for E. coli at 37 °C when compared with a silicone rubber control surface after 
one week of testing.  This type of coating is thus expected to be applied as a potentially 
coating on short-term indwelling devices such as catheters to reduce infection rates.   
Since the influence of NO release profiles on the antibiofilm properties of the NO 
coatings in a flowing system has hardly been reported, this work also serves as a model 
for fundamental studies.  
NO release coatings, however, have short lifetimes due to a limited NO donor reservoir 
that can be incorporated into the polymeric coatings.  To solve this problem, various NO 
generation coatings with covalently attached organodiselenides
4, 5
 and Cu(II)-cyclen 
segments
6, 7
 or doped Cu nanoparticles (NPs)
8
 have been developed in this group to 
convert endogenous NO donors such as S-nitrosothiols (RSNOs) into NO.  The 
previously developed NO generation coatings, however, have had limited applications 
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due to the following factors: 1) the aliphatic selenium species utilized in previous NO 
generation coatings can exhibit cytotoxicity issues; 2) the Cu(II)-cyclen complex-based 
NO generation polymers have limited lifetimes and the NO generation mechanism is not 
clear; and 3) the corrosion rate of Cu NPs are too fast and will lead to potential toxicity 
issues and shorten the lifetimes of Cu NPs-based NO generation coatings.  Therefore, in 
this dissertation, two new types of NO generation coatings based on aromatic selenium 
species and CuO NPs were explored to reduce the toxicity issue and improve the 
lifetimes of previously developed NO generation coatings.   
In Chapter 3, a carboxyl derivative of the drug ebselen, an antioxidant drug that is 
currently undergoing Phase III clinic trial in Japan due to its low toxicity,
9
  was 
successfully synthesized.  By attaching this derivative onto polyethylenimine (PEI), a 
Layer-by-Layer (LbL) coating was then fabricated by using the ebselen-PEI as the 
polycation and alginate as the polyanion.  After a two-step annealing treatment, the LbL 
film exhibits significantly reduced selenium leaching.  The potential antithrombotic and 
antimicrobial properties of the annealed films were further evaluated.  A polyurethane 
catheter coated with 50 bilayers of the annealed LbL films exhibits an NO flux of 310
-10
 
mol cm
-2
 min
-1
 when bathed in physiological levels of RSNOs and thiols, indicating the 
potential antithrombotic properties of the LbL coatings.  In vitro antimicrobial tests also 
proved the capability of the LbL films in reducing bacterial surface attachment and 
killing a broad spectrum of bacterial species through superoxide production.  This type of 
coating, with reduced toxicity, is expected to be a dual functional coating that can be 
further applied to indwelling devices to solve thrombus and infection related 
complications.  In addition, due to the utilization of covalently attached ebselen segment 
and endogenous NO donors, this type of coating is expected to be applied for both short-
term indwelling devices such as catheters and long-term indwelling devices such as 
vascular grafts and stents, and in-vivo studies need to be performed in the future before 
the potential applications. 
The previous mechanism for the catalytic activity of Cu(II)-cyclen-based polymers are 
vague.  Therefore, in Chapter 4, it was first demonstrated that Cu(II)-cyclen-based 
polyurethane (PU) has better catalytic activity compared with the Cu(II)-cyclen 
complexes or its derivative through a series of mechanistic studies.  The improved 
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catalytic activity likely comes from the leaching of Cu(I) from the polymer due to the 
inability of the cyclen ring to stabilize Cu(I).  Based on these findings, copper particle-
based NO generation materials, with a larger copper reservoir, are expected to be the 
alternatives to improve the lifetime of copper-based NO generation materials.  The 
RSNO catalytic decomposition activities and leaching of copper from CuO NPs-doped 
PU films were studied and compared with Cu
0
 NPs-doped PU films.  The CuO NPs-
based PU films with a slower corrosion rate exhibit lower leaching of copper without a 
“burst” of NO generation compared with the Cu
0
 NPs-based PU films, and greatly 
reduced the toxicity issues.  In addition, the catalytic activity of the CuO NPs-based PU 
film lasts for sixteen days and the lifetime is expected to be further extended by changing 
the film formulation.  This type of coating, with CuO NPs as the novel catalyst, is 
expected to be an alternative to previously developed NO generation coatings based on 
various copper species.  Compared to the organoselenium species-based NO generation 
coatings, the CuO NPs-based NO generation coating developed in this dissertation work 
has limited lifetime and can only be applied on short-term indwelling devices such as 
catheters.  However, the advantage of this type of coating lies in its cheap cost and 
simplicity of fabrication.  Since ParaGard IUD (intrauterine device) based on copper 
releasing has been commercialized and approved by FDA,
10
 additional properties and 
applications of the CuO NPs-based polyurethane coatings need to be further examined in 
the future. 
5.2 Future Directions 
5.2.1 Ebselen-based polyurethane for NO generation 
In Chapter 3, a carboxyl-ebselen-based LbL film was shown to exhibit potential 
antithrombotic and proven antimicrobial properties.  In addition to LbL coatings, 
elastomers, such as PUs, are widely utilized in biomedical applications due to their good 
mechanical strength, ease for modification for biocompatibility improvement and 
flexibility in processing.
11
  Therefore, it should be possible to attach ebselen derivatives 
onto different PU matrices to fabricate selenium-based NO generation coatings.  The 
resulting materials are expected to exhibit potential antithrombotic and antimicrobial 
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properties as previously observed for the ebselen-based LbL coatings as described in 
Chapter 3.   
To attach the carboxyl-ebselen segment to PU, one approach would be to aminate the 
PU matrix using a previously reported method
6
 followed by reacting the carboxyl-ebselen 
with the amino group in the modified PU as shown in Scheme 5.1.  This approach, 
attempted in preliminary studies of this dissertation research, resulted in a polymer with 
only 0.08 wt% Se content (experimental data from ICP-OES), indicating limited 
attachment of the ebselen segments onto the polymer matrix.  
 
 
 
Scheme 5.1. Synthesis of ebselen-PU utilizing a three-step approach similar to that is 
previously reported.
6
 
 
The poor attachment rate of carboxyl-ebselen in the previous attempts might be due to 
the cross-linking reactions that take place during the two-step synthesis of the aminated 
PU.  Therefore, to reduce cross-linking before the attachment of the ebselen derivative, 
an improved two-step synthesis route is proposed, as shown in Scheme 5.2.  In reducing 
the synthesis route from three steps to two steps, this proposed approach is expected to 
reduce the cross-linking during the PU modification and improve the attachment of 
catalytic sites onto the PU matrix.  
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Scheme 5.2. Proposed two-step synthesis route for ebselen-PU. 
 
5.2.2 Cu(II)-tris(2-pyridylmethyl)amine-based polymers for NO generation 
In Chapter 4, it was demonstrated that neither Cu(II)-cyclen or the Cu(II)-cyclen amide 
derivative has good catalytic activity towards RSNOs due to their very negative reduction 
potentials.  In addition, the cyclen structure is unable to stabilize Cu(I) as reported 
previously.
12
  Therefore, better chelating agents should be developed to incorporate 
Cu(II)-complexes into a polymer phase.  There are several requirements for a good 
chelating agent: a) the chelating agent should be able to stabilize Cu(I) to prevent any 
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leaching problems; b) the reduction potential of the Cu(II)-complex should not be too 
negative to cause a significant loss of catalytic activity; and c) the Cu(II)-complex should 
still have open sites to interact with reducing agents and RSNOs.  Different from Cu(II)-
cyclen, a Cu(II)-TPA (see structure in Figure 5.1A, TPA= tris(2-pyridylmethyl)amine) 
complex that has been reported to exhibit a more positive reduction potential of -0.34V 
(vs. Ag/AgCl)
13
 and it has also been reported that that d-π transfer can help to stabilize 
Cu(I).
14
  The catalytic activity of Cu(II)-TPA complexes towards RSNOs was examined 
in HEPES buffer containing 20 M EDTA, 50 M GSH and 50 M GSNO and shown in 
Figure 5.1B.  The complex exhibits good catalytic activity towards RSNOs and the 
conversion rate is ~100%, which is much better than those observed with the Cu(II)-cycle 
complex or its derivative, that hardly exhibit any catalytic activity under the same 
conditions.   
 
 
Figure 5.1. A) Structure of tris(2-pyridylmethyl) amine (TPA); B) Catalytic NO 
generation in a solution of 20 M EDTA, 50 M GSH, 50 M GSNO, 50 M Cu(II)-
TPA (1:5, TPA in excess) in 0.1 M HEPES buffer (pH=7.4). 
 
Based on the above observation, TPA derivatives, such as an amine derivative that can 
be synthesized using a reported method
15
 (and potentially attached onto polymers) may 
provide the best approach to develop Cu(II)-complex-based NO generation materials with 
enhanced catalytic activity and longer lifetimes compared with Cu(II)-cyclen-based 
polymers.  A proposed schematic synthesis route for such polymers is shown in Scheme 
5.3.  Copper (II) can be incorporated onto the TPA-based polymer to develop NO 
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generation polymers based on the immobilized Cu(II)-TPA complexes using a previously 
reported method. 
6
  
 
 
Scheme 5.3. Schematic illustration of synthetic route of TPA-based polymers with the 
amine derivative of TPA being synthesized using a reported method.
15
 
 
5.2.3 Combined coating based on NO generation and RSNO release materials 
One of the limitations of utilizing NO generation materials for biomedical applications 
lies in the limited and variable amounts of the RSNO reservoirs in human blood.
16
  
Although it has been previously demonstrated that RSNOs, such as S-nitroso-N-
acetylpenicillamine (SNAP), can be infused to improve the antithrombotic performance 
of NO generation coatings,
8
 a more convenient method will be to combine the NO 
generation material with a RSNO release material into one coating.   
As described in Chapter 1, RSNOs can be doped
17
 within or covalently
18-20
 attached to 
polymers to fabricate NO release coatings.  The NO release of the RSNO release coatings 
can then be trigged through heat or light.  Despite the known catalytic activity towards 
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RSNO, the NO generation polymeric materials that have been developed previously, 
have not been combined with the RSNO release materials.  
In Chapter 4, it was demonstrated that a CuO nanoparticles (NPs)-doped polyurethane 
(PU) film can potentially be utilized as an alternative to previously developed copper-
based NO generation materials.  This coating can be further utilized as a model system to 
devise a combination coating that has an RSNO release under-layer and a top layer 
composed of CuO NPs to generate NO from the RSNO species released from the under-
layer.  
 
Figure 5.2. Configuration of a coating that combines RSNO release and NO generation 
materials. The coating contains a RSNO release layer as the base layer, an adhesive layer 
and an NO generation layer-based on CuO NPs-doped PU films. 
 
A proposed coating configuration is shown in Figure 5.2.  First, the coating contains a 
RSNO release coating as the base layer.  This layer can be composed of the previously 
developed RSNO release materials
17-20
 or a SNAP-doped Elast-Eon
TM
 2As (E2As, from 
AorTech Biomaterials) film that have been developed recently by Elizabeth Brisbois in 
the Meyerhoff group.  An NO generation film is utilized as the top coating.  For example, 
it can be the CuO NPs doped SP-60D-60 PU film.  The polymer matrix applied in the top 
coating should have adequate water uptake so that reducing agents and released RSNO 
can further enter the top layer and interact with the catalytic sites within the top coating.  
Since the water uptake of the base layer, such as the SNAP releasing film, is normally 
much lower when compared with the polymer utilized in the top coating, an adhesive 
layer is necessary to combine the base layer and top coating as well as to prevent direct 
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contact of the catalytic sites with RSNOs to reduce the burst of NO at the initial stage of 
NO release.  The adhesive layer can be comprised of silane compounds such as -
aminopropyltrimethoxysilane as previously utilized in commercial glucose sensors.
21
 
In summary, this thesis has laid the foundation for developing antithrombotic and 
antimicrobial coatings based on NO release or generation.  The developed coatings are 
expected to be applied to short-term indwelling devices such as catheters to solve 
thrombus or infection related biocompatibility issues.  The NO generation coatings, with 
improvements as indicated in the future directions, are expected to be further applied to 
long-term implants, such as vascular grafts, stents, etc. 
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Appendix   Diazeniumdiolate-Doped Poly(lactic acid)-Based    
Biodegradable Nitric Oxide Release Film 
 
A.1 Introduction 
Metals, such as titanium, titanium alloys and magesium alloys have been widely used 
in biomedical applications.
1, 2
  For example, due to their good fatigue strength, relative 
low modulus and shape memory phenomenon, titanium and its alloys have been utilized 
in the fabrication of prosthetics such as artifical hip joints (shown in Figure A.1A) and 
cadiovascular devices such as stents (shown in Figure A.1B).
1
  
 
 
Figure A.1. Schematic diagram of A) artificial hip joint; B) vascular stents.
1
 
 
As described in Chapter 1, bacterial infection is a common problem for indwelling 
devices.  The annual infection rate in the United States is reported to be 4.3% for 
orthopedic implants and 7.4% for cardiovascular implants.
3
  In Chapter 2, it was 
demonstrated that diazeniumdiolate-doped poly(lactic-co-glycolic acid) (PLGA)-based 
NO release films are capable of preventing biofilm formation.  PLGA or PLGA-based 
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drug-eluting coatings have also been applied on metal implants to slow down the 
corrosion of the implants, improve fracture healing and prevent restenosis.
4-6
  Therefore, 
in this appendix, effors to create a totally biodegradable NO releasing film based on 
diazeniumdiolate of spermine (SPER/NONOate) and poly(lactic acid) (PLL) can be 
fabricated and this type of film is expected to be further applied on indwelling metal 
implants to prevent bacterial infection problems after implantation.  Diazeniumdiolated 
spermine is chosen because the degradation product spermine is a naturally occruing 
polyamine, which greatly reduces toxicity concerns for the films developed here. 
A.2 Experimental 
A.2.1 Materials 
Poly(lactic acid) (PLL) (100 DL 7E) was purchased from Lakeshore Biomaterials 
(Birmingham, AL).  The residual monomers were determined as 2 wt% (information 
provided by the vendor). Ca(OH)2, Mg(OH)2, L-arginine (free base), bromothymol blue 
(BB) and anhydrous THF were purchased from Sigma-Aldrich (St. Louis, MO).  
Spermine NONOate (SPER/NONOate) was obtained from Cayman Chemical (Ann 
Arbor, MI).  SPER/NONOate and PLL were stored in a desiccator at -20 °C before use. 
A.2.2 Evaluation of film pH change of PLL films doped with different bases 
Two hundred mg of PLL was dissolved in 3 mL THF and different bases including 
Ca(OH)2, Mg(OH)2 and arginine were then dispersed into the PLL solution to reach a 
final base concentration of 5 wt%, 10 wt% or 20 wt%.  The dispersions were sonicated 
until homogeneous dispersions were formed.  A solution of bromothymol blue (BB) in 
THF (5 mM) was then added into the dispersions to reach a final indicator concentration 
of 10 mmol kg
-1
 as previously described in Chapter 2.
7
  Glass slides (0.9  5 cm) were 
cleaned by sonicating in acetone, deionized water and acetone sequentially and dried 
before use.  Two hundred L of each of the PLL-base dispersions was then cast onto a 
glass slide and the films were then left dry overnight in a desiccator.  The films were then 
placed into PBS buffer and the colors of the films were evaluated at different time 
intervals.  
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A.2.3 Preparation of biodegradable NO release films 
Two hundred mg of PLL was dissolved in 3 mL anhydrous THF, and Ca(OH)2 was 
then added into the solution to reach a final base percentage of 10 wt%.  The dispersion 
was sonicated to obtain a homogeneous dispersion and 200 L of the dispersion was then 
cast onto a glass slide as a base layer (100 L of the dispersion was added at a time).  
SPER/NONOate (2.13 mg) was added into 500 L of the dispersion of 10 wt% Ca(OH)2 
in PLL to obtain a dispersion containing 5 wt% of SPER/NONOate.  The dispersion was 
then sonicated and 25 L of the dispersion was added into an O-ring (d=7 mm) onto the 
base layer.  The film was then dried in a desciccator and this procedure was repeated 
another three times until 100 L of the total dispersion was cast on top of the base layer 
as the NO release layer.  Two hundred L of the dispersion of 10 wt% Ca(OH)2 in PLL 
was then added as a top coating (100 L of the dispersion was added at a time) to 
fabricate the final multilayer film (film A).  A comparison film (film B) was also 
prepared using the same method except a solution of 600 mg PLL in 3 mL THF with 10 
wt% Ca(OH)2 was used to prepare the base layer and the top coating.  The films were 
dried in a desciccator for 6 h and then in vacuum for 2 d before use.   
A.2.4 NO release measurement 
The NO release profiles of the film were measured by purging N2 into 2 mL PBS 
buffer solution, pH 7.4, in a glass cell protected from light and monitored using a 
chemiluminescence NO analyzer (NOA) (Sievers 280, Boulder, CO) as previously 
described in Chapter 2.   
A.3 Result and Discussion 
A.3.1 Comparison of pH changes of PLL films containing different bases 
As described in Chapter 1, in previous reports, small molecular diazeniumdiolates 
(NONOates) such as proli/NONOate and SPER/NONOate (see structures in Figure 
1.5B) have been infused into animals due to the non-toxic amino acids or polyamines 
generated once NO is released from these two NONOates.
8
  Without the presence of any 
base, the lifetimes of the NONOates are very short (2 s for proli/NONOate and 5-50 min 
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for SPER/NONOate in PBS buffer at 37 C).
9
  Therefore, basic solutions such as NaOH 
solution
10
 or solid bases such as Mg(OH)2 
11
 need to be utilized to further extend the 
lifetimes of such NONOates. 
In this experiment, SPER/NONOate was chosen because of its relatively long half-life.  
In Chapter 2, it was demonstrated that there is a correlation between the NO release 
lifetime and the film pH change utilizing bromothymol blue (BB) as the pH indicator.  
The higher the film pH, the slower the depletion of the NO donors within the NO release 
film and thus the longer the NO release lifetime.  Therefore, before the addition of 
SPER/NONOate, the pH changes of films of the PLL matrix doped with different bases 
were evaluated. 
 
Figure A.2. Comparison of color changes of bromothymol blue (BB) doped films 
containing 5 wt%, 10 wt% or 20 wt% of Ca(OH)2, Mg(OH)2 or arginine (free base) at 37 
°C in PBS buffer for 0 min, 1 h, 2 h, 4 h, 6 h and 24 h, respectively. 
 
As shown in the comparison of the film colors in Figure A.2, only the PLL films with 
Ca(OH)2 doped within exhibit a basic environment when the films are placed into PBS 
buffer.  This basic environment is important to reduce the “burst” of NO at the initial 
stage of NO release and stabilize the NONOate within the film once SPER/NONOate is 
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added.  Although the PLL film containing 20 wt% of arginine also exhibits observable 
basic regions, the soluble base of arginine quickly leaches out into the solution within 1 h 
as can be observed in Figure A.2.  Compared to Ca(OH)2, Mg(OH)2, a weaker base, is 
only able to create a neutral environment after gradual water uptake of the film after ~1 h, 
which is not enough to maintain the stability of the NONOate at the initial stage of the 
NO release.  As demonstrated in Chapter 2, the addition of a base into the PLL matrix is 
also able to facilitate the hydrolysis of the ester groups of the polymer matrix.  Therefore, 
while too little Ca(OH)2 will not fully neutralize the acid after its hydrolysis, too much 
base will also over-expedite the hydrolysis of the PLL matrix.  Therefore, the ratio of 
Ca(OH)2 and PLL have to be optimized to obtain the film that can maintain a basic 
condition for the longest time before the addition of SPER/NONOate.  From the 
comparisons of the pH induced color changes shown in Figure A.2 for the PLL films 
doped with different weight percentages of Ca(OH)2, a film containing 10 wt% Ca(OH)2 
is the optimal.    
 
A.3.2 NO release profiles of biodegradable NO release films 
The NO release profiles of the biodegradable NO release films with different top 
coating thicknesses are compared and shown in Figure A.3A and Figure A.3B.  Both 
films contain an NO releasing layer containing 5 wt% of SPER/NONOate doped in a 
matrix also containing 10 wt% of Ca(OH)2 in PLL that is sandwiched between two layers 
of 10 wt% Ca(OH)2 in PLL.  Both the base layer and top coating of film B are three times 
thicker than those of film A.  The NO release profiles of the films, however, are similar.  
According to the integration of the total amount of NO that is released from the films, 
only ~13% of the SPER/NONOate is fully converted to NO.  The low efficiency is 
observed for both films and might be attributed to the preparation method used during 
which the SPER/NONOate has to be exposed to ambient moisture for a long time, 
resulting in loss of NO during the drying process. 
To further evaluate the pH changes within the film during the NO release period, a film 
containing the pH probe in the sandwiched layer was prepared utilizing the same method 
as film A and the color change of the film was monitored over 24 h and compared with 
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the previously observed result in Figure A.2 for a film with 10 wt% Ca(OH)2 doped in 
PLL without the sandwich configuration.  As shown in Figure A.3C, the color changes 
of both films are almost identical and the degradation of the PLL matrix begins to be 
observed between the 4 h and 6 h period of incubation.  This trend is consistent with the 
NO release pattern of the film.  As shown in Figure A.3A, the NO flux is low at the 
initial stage due to the high film pH, but increases significantly after 5 h due to the 
degradation of the PLL matrix, which produces more protons to facilitate the NO release 
of the NONOate.  Film B, with a thicker top coating and base layer, does not show any 
observable NO release until after 5 h.  The thicker barrier is responsible for slower water 
uptake into the middle layer and releases the NO from the NONOate.  The film 
appearance after the pH experiment is shown in Figure A.3D with no significant leaching 
of the pH probe into the PBS buffer is observed.  
 
 
Figure A.3. NO release profiles of A) film A and B) film B in PBS buffer at 37 C.  Both 
biodegradable NO release films containing a sandwiched middle layer of 5 wt% 
SPER/NONOate in 10 wt% Ca(OH)2 doped in PLL matrix (see section A.2.3 for details 
of film preparation). The thickness of the top coating and base layer of film B are three 
times that of film A; C) comparison of film pH changes overtime for films with a 
sandwich configuration and film used in Figure A.2; D) appearance of the film with a 
sandwich configuration after the pH experiment in PBS buffer for 24 h at 37 C. 
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A.4 Conclusions 
Firstly, biodegradable matrices with basic environments can be created by doping 
bases into PLL and this approach can be utilized to extend the NO release lifetimes of 
embedded NONOates.  A completely biodegradable NO release film was fabricated by 
doping spermine NONOate into a matrix composed of 10 wt% Ca(OH)2 in PLL.  The 
film is capable of releasing NO for 20 h at 37 C and is thus expected to be potentially 
applied on metal implants to help solving the bacterial infection issues associated with 
conventional orthopedic implants. 
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